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Abstract 
Post-translational modifications such as ubiquitination are important for orchestrating the 
cellular transformations that occur as the Leishmania parasite differentiates between its main 
morphological forms, the promastigote and amastigote. 2 E1 ubiquitin-activating (E1), 13 E2 
ubiquitin-conjugating (E2), 79 E3 ubiquitin ligase (E3) and 20 deubiquitinating cysteine 
peptidase (DUB) genes can be identified in the Leishmania mexicana genome but, currently, 
little is known about the role of E1, E2 and E3 enzymes in this parasite. Bar-seq analysis of 
23 E1, E2 and HECT/RBR E3 null mutants generated in promastigotes using CRISPR-Cas9 
revealed numerous loss-of-fitness phenotypes in promastigote to amastigote differentiation 
and mammalian infection. The E2s UBC1/CDC34, UBC2 and UEV1 and the HECT E3 ligase 
HECT2 are required for the successful transformation from promastigote to amastigote and 
UBA1b, UBC9, UBC14, HECT7 and HECT11 are required for normal proliferation during 
mouse infection, with ǻubc2 DQG ǻuev1 exhibiting the most extreme loss-of-fitness 
phenotypes. Null mutants could not be generated for the E1 UBA1a or the E2s UBC3, UBC7, 
UBC12 and UBC13, suggesting these genes are essential in promastigotes. X-ray crystal 
structure analysis of UBC2 and UEV1, orthologues of human UBE2N and UBE2V1/UBE2V2 
respectively, reveal a heterodimer with a highly conserved structure and interface. 
Furthermore, recombinant L. mexicana UBA1a can load ubiquitin onto UBC2, allowing UBC2-
UEV1 to form K63-linked di-ubiquitin chains in vitro. Notably, UBC2 can cooperate in vitro with 
human E3s RNF8 and BIRC2 to form non-K63-linked polyubiquitin chains, showing that UBC2 
can facilitate ubiquitination independent of UEV1, but association of UBC2 with UEV1 inhibits 
this ability. Our study demonstrates the dual essentiality of UBC2 and UEV1 in the 
differentiation and intracellular survival of L. mexicana and shows that the interaction between 
these two proteins is crucial for regulation of their ubiquitination activity and function.  
Author summary 
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The post-translational modification of proteins is key for allowing Leishmania parasites to 
transition between the different life cycle stages that exist in its insect vector and mammalian 
host. In particular, components of the ubiquitin system are important for the transformation of 
Leishmania from its insect (promastigote) to mammalian (amastigote) stage and normal 
infection in mice. However, little is known about the role of the enzymes that generate ubiquitin 
modifications in Leishmania. Here we characterise 28 enzymes of the ubiquitination pathway 
and show that many are required for life cycle progression or mouse infection by this parasite. 
Two proteins, UBC2 and UEV1, were selected for further study based on their importance in 
the promastigote to amastigote transition. We demonstrate that UBC2 and UEV1 form a 
heterodimer capable of carrying out ubiquitination and that the structural basis for this activity 
is conserved between Leishmania, Saccharomyces cerevisiae and humans. We also show 
that the interaction of UBC2 with UEV1 alters the nature of the ubiquitination activity performed 
by UBC2. Overall, we demonstrate the important role that ubiquitination enzymes play in the 
life cycle and infection process of Leishmania and explore the biochemistry underlying UBC2 
and UEV1 function. 
Introduction 
Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania. 
This disease, which has a tropical and sub-tropical distribution, is transmitted by the bite of a 
sandfly and causes around 70,000 deaths annually (1). During their complex, digenetic life 
cycle, Leishmania differentiate between two main morphological forms: the motile, 
extracellular promastigote form in the sand fly vector and the non-motile, intracellular 
amastigote form in the mammalian host. Of the numerous promastigote forms that exist in the 
sandfly, procyclic promastigotes are the most actively dividing and metacyclic promastigotes 
are the transmissible form (2). In order for Leishmania cells to transition between the disparate 
environments of the sandfly mouthparts and mammalian phagolysosomes, substantial 
changes in gene expression, particularly at the post-transcriptional level, are required (3, 4). 
4 
 
The post-translational modifications phosphorylation and ubiquitination, for example, are 
thought to contribute significantly to the differentiation process (5-8). 
Ubiquitination regulates numerous cellular processes including proteasomal degradation, 
endocytic trafficking and DNA repair (9). Addition of the 8.5 kDa protein ubiquitin (Ub) to 
proteins is carried out by the sequential actions of E1 ubiquitin-activating (E1), E2 ubiquitin-
conjugating (E2) and E3 ubiquitin ligase (E3) enzymes. Typically, an E1 activates ubiquitin in 
an ATP-dependent manner by adenylating its C-terminus, allowing a thioester bond to form 
between the E1 active site and ubiquitin. Subsequently, ubiquitin is transferred to the active 
site of an E2 via trans-thioesterification and then onto the substrate with the help of an E3 
ligase. Most commonly, ubiquitination occurs on a lysine residue, although modification of 
cysteine, serine, threonine and the N-termini of proteins are also possible (10). E3 ligases can 
be grouped into two categories based on their mechanism of action. Cys-dependent E3s such 
as the HECT (Homologous to the E6-AP Carboxyl Terminus) and RBR (Ring-Between-Ring) 
E3s contain a cysteine residue that forms a thioester bond with ubiquitin prior to transfer to 
the substrate. Conversely, Cys-independent E3s such as the RING (really interesting new 
gene) and U-box E3s facilitate the direct transfer of ubiquitin between E2 and substrate by 
providing a scaffold that orients the ubiquitin-charged E2 relative to the substrate (11). 
Ubiquitin-like modifiers (Ubls) such as SUMO and Nedd8 have a similar, but distinct, E1-E2-
E3 conjugation pathway to that of ubiquitin (12). The removal of ubiquitin modifications is 
carried out by deubiquitinating enzymes (DUBs) (9). 
A huge diversity of ubiquitin modifications exists, due in part to the ability of ubiquitin itself to 
be ubiquitinated on any of the epsilon amino groups of its 7 lysine side chains or on the alpha 
amino group of its N-terminus. This allows for the formation of linear or branched polyubiquitin 
chains. Acetylation, phosphorylation and the modification of ubiquitin with other Ubls (including 
SUMO and Nedd8) are also possible (13). The huge array of potential modifications permits 
a range of signalling outcomes. For example, K48-linked chains, the most common ubiquitin 
chain type, target proteins for proteasomal degradation. In contrast, K63-linked chains 
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typically provide a non-degradative signal, for example in promoting the recruitment of proteins 
to sites of DNA damage (9). 
To date, two ubiquitin-activating enzymes have been described in Leishmania major (14), and 
at least 20 cysteine peptidase DUBs exist in Leishmania mexicana, many of which are 
essential for the promastigote to amastigote transition (8). The importance of the ubiquitination 
system in these species is further exemplified by the finding that the Leishmania proteasome 
is essential for parasite survival, since many forms of ubiquitin modification target proteins for 
proteasomal degradation (15). The L. major Atg8 and Atg12 Ubls have been shown to play a 
role in parasite autophagy (16, 17) and, although they have yet to be properly described in 
Leishmania, SUMO- and Nedd8-conjugation systems exist in the closely-related kinetoplastid 
Trypanosoma brucei (18-23). The Ubls Ufm1 and Urm1 also exist in Leishmania (24-26). 
However, little is currently known about the role that ubiquitin E1, E2 and E3 enzymes play in 
Leishmania biology. In this study we characterise the E1, E2 and E3 enzymes of L. mexicana 
by analysing the fitness of an E1, E2 and HECT/RBR E3 null mutant library throughout the 
Leishmania life cycle. We show that, amongst others, the E2 ubiquitin-conjugating enzyme 
UBC2 and the ubiquitin E2 variant UEV1, are essential for the promastigote to amastigote 
transition and subsequently characterise these proteins in biochemical and structural detail. 
Results 
Ubiquitination gene families in L. mexicana 
Initial analysis of the L. mexicana genome using Interpro and PFAM domain searches 
identified 4 ubiquitin-activating E1 (UBA), 15 ubiquitin E2-conjugating (UBC) and 81 E3 ligase 
genes (S1 Table). The putative E3s included 14 HECT, 1 RBR, 57 RING, 4 RING-CH-type 
and 5 U-box E3s. Upon more detailed analysis, however, LmxM.08.0220 and LmxM.02.0390 
were found to be orthologues of T. brucei Uba2 and Ubc9, which have been identified as an 
E1 catalytic subunit and E2 enzyme for the Ubl SUMO respectively and were named UBA2 
6 
 
and UBC9 based on this orthology (21). Similarly, LmxM.01.0710 (UBA3) was found to share 
more similarity with HsUBA3 (68% query cover, 35.8% identity, E value: 8e-64), a Nedd8-
activating enzyme catalytic subunit, than the ubiquitin E1 HsUBA1 (46% query cover, 31.7% 
identity, E value: 3e-25) and LmxM.24.1710 (UBC12) appears to be an orthologue of T. brucei 
Ubc12, an E2 Nedd8-conjugating enzyme (23). For two of the HECT domain-containing 
genes, HECT13 and HECT14, only partial HECT domains of 69 and 60 amino acids were 
identified respectively, suggesting that they do not function as E3s. Following the removal of 
Ubl E1 and E2s and possible pseudo-HECTs from the list of identified ubiquitination genes, 2 
ubiquitin E1s, 13 ubiquitin E2s and 79 E3 ligase genes were proposed to be present in the L. 
mexicana genome. Of these, UBC1, a ubiquitin E2, is related to T. brucei CDC34 (99% query 
cover, 55.2% identity, E value: 2e-105), required for cytokinesis and infection progression of 
bloodstream form parasites in mice (27). UBC4, also a ubiquitin E2, is related to T. brucei 
PEX4 (100% query cover, 58.6% identity, E value: 5e-72), implicated in the ubiquitination of 
TbPEX5, a cytosolic receptor involved in peroxisome biogenesis (28).   
Of the putative ubiquitination genes identified, the predicted molecular weights of encoded 
proteins range from between 115-127 kDa for E1s, 16-49 kDa for E2s, 147-733 kDa for HECT 
E3 ligases and 9-288 kDa for RING, RING-CH-type and U-box E3 ligases. Only one RBR-
type E3 ligase, with a predicted molecular weight of 58 kDa, was identified. An alignment of 
UBA1a and UBA1b with human ubiquitin-activating E1 enzymes (S1A Fig) revealed 
conservation of the catalytic cysteine residue (C596 in UBA1a and C651 in UBA1b, equivalent 
to C632 in HsUBA1). Similarly, an alignment of L. mexicana and human E2-conjugating 
enzymes showed conservation of the conserved catalytic cysteine in all L. mexicana E2s 
except UEV1 (S1B Fig), suggesting the latter is a non-catalytic ubiquitin E2 variant (29). 
Furthermore, the HPN (His-Pro-Asn) motif, which is conserved in human E2-conjugating 
enzymes and which contains an asparagine residue that can be important for catalysis (30-
32), was found to be partially or completely missing in UBC3, UBC6, UBC11, UBC14 and 
UEV1. A HECT domain alignment for L. mexicana HECT E3 ligases and 4 human HECT E3 
7 
 
ligases showed that HECTs 1-12 contained the conserved catalytic cysteine residue. 
Consistent with the identification of a partial HECT domain in HECT13 and HECT14, a putative 
catalytic cysteine was absent in these sequences (S1C Fig).  
A bar-seq screen reveals the importance of ubiquitination genes in the L. 
mexicana life cycle 
In order to investigate the role of ubiquitination, SUMOylation and Neddylation genes in the 
life cycle of L. mexicana, the 4 E1, 15 E2 and HECT and RBR subgroups of E3 genes (12 and 
1 gene respectively) from our bioinformatics analysis were targeted for deletion in procyclic 
promastigotes using CRISPR-Cas9 (33). The resistance cassettes used for integration into 
the targeted gene locus contained unique, 12 nucleotide barcodes to allow for the identification 
of individual null mutant lines in a pooled library. Details of the primers and plasmids used are 
provided in S2 Table. Null mutant lines were validated using PCRs to detect removal of the 
gene of interest and integration of the blasticidin resistance cassette (S2A Fig and S2B Fig) 
and, where a null mutant was not immediately generated, three rounds of transfection were 
performed to reduce the likelihood of not obtaining a null mutant line due to technical failure. 
$ VLPLODU VWUDWHJ\ ZDV XVHG IRU WKH JHQHUDWLRQ RI D ǻhect12 mutant but will be described 
elsewhere. In this way, null mutants were generated for all genes except UBA1a, UBC3, 
UBC7, UBC12 and UBC13, suggesting that 1 out of 2 ubiquitin E1s and 4 out of 13 ubiquitin 
E2s may be essential in promastigotes. Although mutant clones were obtained for UBA1a, 
UBC3, UBC7 and UBC12, they still contained the gene of interest (S2C Fig). This lends further 
support to the proposition that UBA1a, UBC3, UBC7 and UBC12 are essential in 
promastigotes, since it suggests that gene duplication events have occurred to allow the 
parasite to retain the gene. Notably, a null mutant was successfully generated for the Nedd8 
E1 UBA3 despite UBC12 (Nedd8 E2) appearing to be essential. This suggests that the 
essential role of UBC12 may be independent of UBA3. None of the SUMOylation, HECT E3 
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or RBR E3 genes were essential in promastigotes, as evidenced by the successful generation 
of null mutants for these genes. 
Next, barcode analysis by sequencing (bar-seq) , which involves the parallel phenotyping of a 
null mutant pool using next-generation sequencing, was used to analyse the null mutants (34). 
Briefly, 58 promastigote-stage null mutants including the 3 E1, 10 E2 (excluding ǻubc5) and 
13 HECT/RBR E3 null mutants alongside 16 DUB, 13 other peptidase and 4 protein kinase 
null mutants were pooled in equal proportions and in 6 replicate samples. Pooled promastigote 
(PRO) cultures were grown for 7 days and then induced to form axenic amastigotes (AXA) or 
used to purify metacyclic stage promastigotes (META). Purified metacyclic cells were used to 
infect macrophages (inMAC) in culture or mice using footpad injection (FP). At the time points 
indicated in Fig 1A, DNA was extracted to allow for amplification of the barcoded regions by 
PCR and quantitative analysis by next generation sequencing; the raw data are available in 
S4 Table in Damianou et al., 2020 (8). The heat maps in Fig 1B-D show the proportional 
representation of each null mutant line at each experimental time point, with a gradient of white 
to red representing proportions ranging between zero and 0.04 (or above) respectively. 
Proportional representation was calculated by dividing the number of reads for an individual 
barcode by the total number of reads for all expected barcodes and averaging over the 6 
replicates. Loss-of-fitness phenotypes were inferred from decreases in proportional 
representation from one time point to WKHQH[W)RUǻuba2, only 2.6 x 106, instead of 4 x 106 
cells, were added to the pools due to the poor prior growth of this cell line. Furthermore, the 
associated barcode was not detected in all of the PRO 0 h time points, perhaps due to the 
lower represenWDWLRQRIǻuba2 in the pool, prompting the decision to exclude this cell line from 
the analysis.  
Between the PRO 0 h and PRO 168 h samples, there was no complete loss of any null mutant 
line from the populations, although several significant loss-of-fitness phenotypes (decreases 
in proportional representation within the population) were observed between adjacent 
timepoints (<0.05, paired t-test, Holm-âtGiNPHWKRGS4 Table, Damianou et al., 2020 (8)). 
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For H[DPSOHUHGXFHGILWQHVVZDVVHHQDWWZRRUPRUHSURPDVWLJRWHWLPHSRLQWVIRUǻubc9, 
ǻhect2 DQGǻhect12. No loss-of-fitness phenotypes were observed between the PRO 168 h 
and META samples or between the PRO 168 h and AXA 24 h samples.  
Within both the AXA 24 h-AXA 120 h and META-inMAC 12 h intervals, loss-of-fitness was 
REVHUYHGIRUQXOOPXWDQWVǻuba1b, ǻubc2, ǻubc6, ǻubc8, ǻubc9, ǻuev1, ǻhect2, ǻhect4, 
ǻhect7 DQGǻrbr1, demonstrating good correlation between these two experiments. Of these, 
strong defects (>3-fold decrease in fitness between both intervals) were observed for 
ǻubc1/cdc34ǻubc2, ǻuev1 and ǻhect2,QDGGLWLRQǻubc4/pex4, ǻubc11, ǻXEFǻhect5, 
ǻhect6, ǻhect11 and ǻhect12 showed loss-of-fitness between the AXA 24 h and AXA 120 h 
samples DQG ǻhect10 showed a reduction in fitness between the META and inMAC 12 h 
samples. Further loss-of-ILWQHVVIRUǻubc8 DQGǻrbr1 was observed between inMAC 12 h and 
inMAC 72 h. All null mutant lines that showed loss-of-fitness defects in the axenic amastigote 
and macrophage samples also had compromised fitness in the mouse, although many of the 
SKHQRW\SHVREVHUYHGZHUHPRUHVHYHUH6SHFLILFDOO\ǻuba1b, ǻubc1/cdc34, ǻubc2, ǻubc9, 
ǻubc14 ǻuev1, ǻhect2, ǻhect7 DQG ǻhect11 had at least 20-fold reductions in fitness 
between the META DQG )3  VDPSOHV $GGLWLRQDOO\ ǻuba3 and ǻhect1 showed small 
decreases in fitness during this interval. Notablyǻubc1/cdc34ǻubc2ǻuev1 DQGǻhect2 
showed the most dramatic and consistent loss-of-fitness phenotypes, including >5-fold, >25-
fold and >200-fold decreases in fitness across the axenic amastigote, macrophage infection 
and mouse infection experiments respectively (calculated between the PRO 168 h/META 
sample and the experimental endpoints). A pBLAST search revealed that HECT2 is related to 
human UBE3C (28% query cover, 35.3% identity, 1e-64 E value), a HECT E3 ligase that 
ubiquitinates proteasome substrates to enhance proteasomal processivity (35). Overall, 
ǻubc2 DQGǻuev1 had the most severe phenotypes with reductions in fitness of 50-fold in the 
axenic amastigote, 300-fold in the macrophage and a complete loss-of-fitness (to zero) in the 
PRXVH7KHVWURQJGHIHFWVREVHUYHGIRUǻubc1/cdc34ǻubc2, ǻuev1 and ǻhect2 in pooled 
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axenic amastigote differentiation were also observed individually using a cell viability assay 
(S2D Fig, S3 Table). 
UBC2 and UEV1 are orthologues of human UBE2N and UBE2V1/UBE2V2 
Since ǻubc2 DQGǻuev1 showed the most severe loss-of-fitness phenotypes in the bar-seq 
screen, we decided to investigate their function. The most probable orthologues of L. 
mexicana UBC2 (LmxM.04.0680) and UEV1 (LmxM.13.1580) were identified in the 
Trypanosoma brucei, Saccharomyces cerevisiae and human genomes using protein BLAST 
searches and the two groups of sequences aligned. Fig 2A shows that there is a high level of 
conservation between UBC2 and its predicted orthologues. Specifically, UBC2 shares 77%, 
66% and 70% amino acid identity with the equivalent T. brucei, S. cerevisiae and human 
proteins respectively. Such a high level of shared identity suggests that UBC2 functions are 
likely to be well-conserved. In contrast, UEV1 is less well conserved with its orthologues, 
sharing 70%, 54% and 47% amino acid identity with the equivalent T. brucei, S. cerevisiae 
and human proteins respectively (Fig 2B). Consequently, there may be more functional 
divergence within this gene family. In humans, UBE2N and UBE2V1/V2 form a heterodimeric 
complex specific for K63-linked ubiquitination and have been linked to inflammatory signalling 
(36) and DNA damage response pathways (37). 
UBC2 and UEV1 encode proteins of 148 and 138 amino acid residues respectively, 
corresponding to predicted molecular weights of 17 kDa and 16 kDa. Based on the alignment 
in Fig 2A, the putative catalytic cysteine of UBC2 is C85, equivalent to C87 in S. cerevisiae 
UBC13 and C87 in human UBE2N (38). UBC2 also contains an HPN motif 10 amino acids N-
terminal of C85 that may be involved in catalysis (30-32). All of the proteins in the UEV1 
alignment (Fig 2B) lack catalytic cysteine residues and HPN motifs, consistent with UEV1 
being part of the noncatalytic UEV family of E2s (29). For the UEV1 alignment, isoform 3 
(canonical sequence in UniProtKB) of UBE2V1 was used as this is the most similar isoform to 
UEV1. However, UBE2V1 is predicted to have numerous isoforms produced by alternative 
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splicing. For example, a 30 residue N-terminal extension of isoform 2 (UEV-1A) relative to 
UBE2V2 has previously been shown to account for their differing functions (39). Since UEV1 
lacks such an N-terminal extension, it could be predicted to be more similar in function to 
UBE2V2 than UBE2V1. 
L. mexicana UBC2 and UEV1 form a heterodimer 
To permit biochemical characterisation of L. mexicana UBC2 and UEV1, His-Im9-tagged (40) 
UBC2 and UEV1 were expressed in Escherichia coli and purified following tag removal. In 
parallel, UBA1a, a putative ubiquitin-activating enzyme and the product of one of our proposed 
promastigote-essential genes, was similarly expressed and purified. Two putative ubiquitin-
activating enzymes exist in L. mexicana, and, like T. brucei UBA1a and UBA1b, are more 
closely related to human UBA1 than UBA6 (14). Specifically, L. mexicana UBA1a and UBA1b 
share 36% and 33% amino acid identity with HsUBA1 respectively and 28% identity with each 
other. Based on its higher shared identity with HsUBA1 and potential essentiality, it was 
reasoned that UBA1a would be more likely to show a broad E2 specificity (comparable to that 
of HsUBA1) and therefore be capable of loading ubiquitin onto UBC2 (41, 42). All 3 proteins 
showed a good level of purity as assessed by InstantBlue staining (Fig 3A). For UBC2 and 
UEV1 no additional proteins were detected, whereas the UBA1a sample contained 2 extra 
proteins at around 74 and 100 kDa. These appeared below UBA1a, suggesting the presence 
of co-purified protein or UBA1a degradation products.  
The orthologues of UBC2 and UEV1 in T. brucei, S. cerevisiae and humans have previously 
been shown to form a heterodimeric complex (43-46). To test whether this was also true in L. 
mexicana, a size-exclusion chromatography multi-angle laser light scattering (SEC-MALLS) 
approach was used. The chromatograms in Fig 3B show peaks in the refractive index 
representing the purified UBC2 and UEV1 samples at 25 and 26 min respectively. 
Measurement of both the refractive index and multi-angle laser light scattering allowed an 
estimation of the molecular weights of the recombinant proteins at 18.7 kDa and 18.2 kDa for 
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UBC2 and UEV1 respectively (dashed lines above peaks in refractive index). These values 
are close to the predicted molecular weights of 17 kDa for UBC2 and 16 kDa for UEV1. That 
both of these proteins eluted as a single peak is indicative of them existing in monomeric form 
while also reflecting the high quality of the protein preparations. When UBC2 and UEV1 were 
mixed in an equimolar ratio, an elution peak was seen at 23 min, indicating the presence of a 
higher molecular weight species (estimated at 34.2 kDa). Given that no peaks were seen 
representing UBC2 and UEV1 monomers, it can be assumed that all protein material in this 
sample existed in heterodimeric UBC2-UEV1 complexes. Therefore, L. mexicana UBC2 and 
UEV1 readily associate to form a heterodimeric UBC2-UEV1 complex. 
Structure of the UBC2-UEV1 heterodimer 
To investigate the conservation and interactions of UBC2 and UEV1 at the structural level, we 
sought crystals of their complex. Crystals, which appeared after two days from polyethylene 
glycol-containing solutions, were sent for data collection at the Diamond Light Source, with 
the best crystal yielding a dataset extending to 1.7 Å spacing. The structure was solved by 
molecular replacement using the coordinates of the human UBE2N-UBE2V2 complex as the 
search model (PDB ID: 1J7D) (47). There are two UBC2-UEV1 heterodimers (PDB ID: 6ZM3) 
in the crystallographic asymmetric unit. These were found to have a similar structure and 
subunit organisation following superposition of chains equivalent to UBC2, UEV1 or the UBC2-
UEV1 heterodimer by secondary structure matching (SSM) procedures, with RMSDs of 0.32 
Å, 0.74 Å and 1.13 Å for 146, 132 and 276 equivalent atoms respectively. Since residues 
Gly20 to Asn24 are poorly defined in the electron density maps for one of the UEV1 chains, 
the alternative UBC2-UEV1 heterodimer was the focus of our analysis.  
Like its S. cerevisiae and human orthologues, UBC2 has a canonical E2 structure comprising 
a 4-stranded antipaUDOOHOȕ-sheet flanked by four Į-helices (Fig 4A). UEV1 exhibits a similar 
topology, but its polypeptide chain is shorter and the prominent pair of Į-helices at the C-
terminus RI 8%& Į DQG Į DUH PLVVLQJ IURP 8(9. Relative to human UBE2V1 and 
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UBE2V2, UEV1 has a shorter segment leading into the ILUVWĮ-helix (Fig 2B), a feature it shares 
with S. cerevisiae Mms2. Superposing UBC2 with human UBE2N, UEV1 with human UBE2V2 
or the UBC2-UEV1 and UBE2N-UBE2V2 heterodimers (S3A Fig) gives RMSDs of 0.82, 1.15 
and 1.13 Å for 147, 135 and 271 equivalent atoms respectively, demonstrating a high level of 
structural conservation between these orthologues. The conserved active site residues, His75, 
Pro76, Asn77 and Cys85, reside on an extended segment of the polypeptide that connects 
strand ȕDQGKHOL[Į of UBC2, with the thiol group of Cys85 projecting out of the catalytic 
cleft (Fig 4B). The high level of sequence conservation around these residues is reflected in 
the close proximity of their superposed catalytic clefts. 
The interface between UBC2 and UEV1 (Fig 4C-D, S3B Fig) LQYROYHV WKH ȕ ȕ DQG ȕ
strands DQGWKHORRSVIROORZLQJȕȕDQGȕRI8%&DQGWKH1-WHUPLQXVĮKHOL[DQGORRS
IROORZLQJȕRI8(97KHEXULHGVXUIDFHDUHDRIWKLVLQWHUIDFHLV1,466 Å2. The core of the 
interface contains a number of hydrophobic residues (Tyr32, Phe55, Leu70 and Val81 of 
UBC2 and Pro5, Phe8, Leu11, Leu14 and Phe39 of UEV1) that contribute strongly to the 
interaction. Hydrophobic residues are highly conserved at these positions (Fig 2), highlighting 
the importance of the associated hydrophobic interactions for complex formation. These 
hydrophobic interactions are complemented by a number of polar intermolecular interactions, 
mostly notably between the side chains of Glu53 of UBC2 and Asn7 of UEV1 and Arg68 of 
UBC2 and the main chain carbonyl oxygen of Ile37 of UEV1. Both of these interactions are 
conserved in the human complex although Met is present in place of Ile. Notably, a salt bridge 
is formed between Arg83 of UBC2 and Glu18 of UEV1. Although these residues are conserved 
in S. cerevisiae, human UBE2V1/2 has Gln in place of Glu. Asp38 and Glu39 residues in 
human UBE2V2 provide hydrogen bonds for the interaction interface but are replaced by Thr 
and Ala (at positions 34 and 35 respectively) in UEV1.  
Ubiquitin transfer occurs between UBA1a and UBC2 in vitro 
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To assess whether UBA1a, UBC2 and UEV1 are an active E1, active E2 and inactive E2 
variant respectively, recombinant proteins were tested in thioester intermediate assays. Fig 
5A shows the results of incubating UBA1a, UBC2 and UEV1 in different combinations in the 
presence of ubiquitin and ATP. In these assays, human ubiquitin, which has 2 amino acid 
substitutions relative to L. mexicana ubiquitin (S4A Fig), was used. When UBA1a was present 
under non-reducing conditions, the appearance of a UBA1a~Ub thioester intermediate (at 
around 125 kDa) was observed over time. Under reducing conditions, this intermediate was 
lost, confirming the presence of thioester-linked UBA1a~Ub. When UBA1a and UBC2 were 
combined under non-reducing conditions, the appearance of an additional protein band at 26 
kDa was observed, suggesting the transfer of ubiquitin between UBA1a and UBC2 to form 
thioester-linked UBC2~Ub. This protein complex was lost under reducing conditions, 
confirming its identity as a UBC2~Ub thioester intermediate. In contrast, when UBA1a and 
UEV1 were combined, no lower mobility species of UEV1 were observed, suggesting that 
UEV1 is unable to receive ubiquitin from UBA1a. When UBA1a, UBC2 and UEV1 were 
combined, no UBC2~Ub thioester intermediate was observed. It was reasoned that UEV1 
could prevent UBC2 from binding ubiquitin or, alternatively, that the presence of UEV1 
facilitates the release of ubiquitin from UBC2 or its transfer onto substrate(s) in solution. 
Conversely, the alternative L. mexicana ubiquitin E1, UBA1b, was unable to transfer ubiquitin 
to UBC2, despite being capable of forming thioester-linked UBA1b~Ub (S4B Fig). UBA1b was 
also unable to transfer ubiquitin onto UEV1 (S4B Fig), showing that ubiquitin cannot be loaded 
onto UEV1 by either of the two L. mexicana ubiquitin E1 enzymes. These results support the 
identities of UBA1a, UBC2 and UEV1 as an active E1, active E2 and inactive E2 variant 
respectively. 
UBC2 and UEV1 conjugate ubiquitin in vitro 
Previous in vitro studies have demonstrated the ability of S. cerevisiae UBC13 and MMS2 and 
their human counterparts to promote the formation of ubiquitin chains in the absence of E3 
enzyme (30, 39, 44, 45, 48). To test whether the L. mexicana enzymes share this ability, 
15 
 
different combinations of UBC2 and UEV1 were incubated with UBA1a, ubiquitin and ATP and 
di-ubiquitin formation monitored by immunoblotting for mono- and poly-ubiquitinated 
conjugates under reducing conditions. This approach was chosen in order to distinguish 
between UBC2, UEV1 and di-ubiquitin, which all have similar molecular weights. Di-ubiquitin 
formation was observed after 30 min in the presence of UBC2 and UEV1 and increased by 90 
min (Fig 5B). In contrast, no di-ubiquitin formation was observed in the absence of either UBC2 
or UEV1, suggesting that both proteins are required for di-ubiquitin formation. An additional 
protein that may represent tri-ubiquitin was observed above di-ubiquitin at the 90 minute time 
point, suggesting that higher order chains may be being assembled. Additionally, since the 
reducing conditions would disrupt any UBC2-Ub thioester intermediates, the protein at around 
26 kDa in samples containing UBC2 may represent auto-ubiquitinated UBC2. Comparably, in 
vitro auto-ubiquitination of human UBE2N on K92, equivalent to K90 in UBC2, has been 
observed (45). Auto-ubiquitinated UBA1a also appears to be present at the top of the blot. 
Since S. cerevisiae UBC13 and MMS2 and their human orthologues have been shown to 
specifically form K63-linked ubiquitin chains (44, 45), the reactions described above were 
additionally probed with a K63 linkage-specific antibody. The right-hand panel in Fig 5B shows 
that K63-linked ubiquitin conjugates are formed by UBC2-UEV1. Furthermore, UBC2 and 
UEV1 were unable to conjugate K63R mutant ubiquitin, demonstrating the essential 
requirement for K63 of ubiquitin in the formation of free ubiquitin chains by UBC2-UEV1 (Fig 
5C). Pre-incubation of UBC2 with the covalent UBE2N inhibitor NSC697923 reduced di-
ubiquitin formation in a concentration-dependent manner, showing that K63-linked ubiquitin 
chain formation is dependent upon UBC2 catalytic activity (Fig 5D). That NSC697923 was 
likely to inhibit UBC2 was rationalised based on the fact that all 4 of the residues that were 
mutated to make UBE2N resistant to NSC697923 are also found in UBC2 (49). Complete 
inhibition of di-ubiquitin formation was not achieved, perhaps due to an insufficiently long 
incubation time for UBC2 with NSC697923. These experiments demonstrate that UBC2 and 
UEV1 can form free K63-linked ubiquitin chains in vitro (Fig 5E).  
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The crystal structure of S. cerevisiae Mms2-Ubc13 covalently linked to a donor ubiquitin 
molecule revealed the structural basis of K63 linkage specificity in ubiquitin chain formation. 
In this structure, Mms2 directs the K63 residue of a putative acceptor ubiquitin into the Ubc13 
active site, where it can attack Gly76 of the donor ubiquitin bound to the Ubc13 active site 
cysteine to form an isopeptide bond (50). An overlay of this structure (PDB ID: 2GMI) with 
chains A and B of our UBC2-UEV1 structure allowed the positions of the donor and acceptor 
ubiquitins to be revealed in the context of the L. mexicana complex (S3C Fig). This produces 
a plausible model of the quaternary complex without significant steric clashes and suggests 
that the same strategy is used to confer Lys63-linkage specificity in L. mexicana and S. 
cerevisiae. In support of this, two Mms2 residues shown to be required for acceptor ubiquitin 
binding in the S. cerevisiae Mms2-Ubc13-Ub structure, Ser27 and Thr44, are conserved in L. 
mexicana UEV1 (Ser28 and Thr45). 
UBC2 can cooperate with human E3s to allow polyubiquitination in vitro 
As the cognate E3s for UBC2 and UEV1 have not yet been identified, human E3s known to 
catalyse ubiquitination in coordination with UBE2N were tested for their ability to similarly 
cooperate with UBC2 and/or UEV1. The reasons for doing this were threefold. Firstly, to 
investigate whether UBC2 could carry out the typical E2 role of facilitating ubiquitin transfer to 
substrates via E3 enzymes. Secondly, in the hope of making inferences about L. mexicana 
E3s that could be part of the UBC2 ubiquitination cascade and, lastly, to explore the 
conservation of E2-E3 interactions between L. mexicana and humans. For this purpose, two 
RING E3 ligases, BIRC2 and RNF8, were selected for testing on the basis that they are known 
to interact with human UBE2N (51-53). In humans, BIRC2 has wide-ranging roles including in 
regulating apoptosis and cell proliferation (51, 54) and RNF8 has well-characterised roles in 
DNA damage signalling (55-57). HUWE1, a HECT E3 ligase that is not known or predicted to 
interact with UBE2N, was also chosen for comparison (58). All recombinant E3s used were 
GST-tagged and, with the exception of HUWE1 which was N-terminally truncated, full-length. 
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Fig 6 shows the ubiquitination profiles observed for BIRC2, RNF8 or HUWE1 incubated with 
different combinations of UBC2 and UEV1 in reactions containing UBA1a, ubiquitin and ATP. 
When BIRC2 or RNF8 were incubated with UBC2 in the absence of UEV1, a prominent pattern 
of polyubiquitination was seen (upper panel). Based on the K63-linked ubiquitin and GST blots 
(middle and lower panels respectively), the polyubiquitination observed was not K63-linked 
and occurred both as a result of E3 auto-ubiquitination and of free chain formation and/or 
ubiquitination of other proteins (such as UBA1a, UBC2 or UEV1) in solution. When BIRC2 or 
RNF8 were incubated with UEV1 in the absence of UBC2, polyubiquitination did not occur. 
However, a single protein was present in the ubiquitin conjugate blot at around 130 kDa, likely 
representing ubiquitinated UBA1a (as observed in Fig 5B-D). Similarly, polyubiquitination was 
not observed when BIRC2 or RNF8 were incubated with both UBC2 and UEV1. In these 
samples, however, di-ubiquitin formation was notably increased, suggesting that UEV1 is able 
to regulate UBC2 such that it switches its activity between facilitating polyubiquitination by E3s 
and forming K63-linked ubiquitin chains in complex with UEV1 (Fig 6B). In contrast, 
polyubiquitination was observed when either UBC2, UEV1 or UBC2 and UEV1 were combined 
with HUWE1, suggesting that physical interaction between E2s and HUWE1 may be required 
for HUWE1 activity. Alternatively, the truncated nature of the recombinant HUWE1 protein, 
which lacks its UBA and WWE protein-protein interaction domains, may have encouraged 
non-specific interaction with and ubiquitin transfer from UBA1a. No ubiquitin conjugates were 
observed in the absence of both UBC2 and UEV1.  
High functional conservation of human and Leishmania enzymes  
In order to further interrogate the functional conservation between Leishmania and human 
enzymes, the ability of UBC2 to extend ubiquitin chains on the human U-box E3 ligase CHIP 
was investigated. In vitro monoubiquitination of CHIP by UBE2W can be followed by the 
extension of ubiquitin chains by UBE2N-UBE2V1 and provides an example of a pair of 
cooperating E2s with distinct chain initiation and elongation functions (59-61). To simplify the 
experimental setup and interpretation of results, it was decided to select a single E1 enzyme 
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to facilitate ubiquitin transfer to both human UBE2W and L. mexicana UBC2. In a thioester 
assay, L. mexicana UBA1a was shown to be equally competent at transferring ubiquitin to 
UBE2W as human UBA1 (Fig 7A) and was therefore selected for use in subsequent 
experiments. In addition to the reducible UBE2W-Ub thioester bands observed, an additional, 
non-reducible band was observed following incubation of E1 and E2 enzymes. This is likely to 
be N-terminally ubiquitinated UBE2W (62, 63). 
When L. mexicana UBC2 and UEV1 were incubated with human UBE2W and CHIP in the 
presence of E1, ubiquitin and ATP, polyubiquitinated CHIP was observed (Fig 7B). When 
UBE2W was absent from this reaction, no CHIP ubiquitination or free chain formation was 
seen. Alternatively, when UBC2 and UEV1 were absent, only monoubiquitinated CHIP was 
observed, suggesting that UBE2W is priming CHIP with a single ubiquitin modification that 
can then be extended by UBC2 and UEV1 (Fig 7C). In this respect, UBC2 and UEV1 behave 
in a similar manner to human UBE2N-UBE2V1 (59). The absence of free chain formation in 
the presence of UBC2, UEV1 and CHIP, however, is in contrast to what was reported for 
human UBE2N-UBE2V1 and CHIP (59, 60). In reactions where UBE2W was present but CHIP 
was absent, a strong band at around 34 kDa was observed, likely corresponding to N-
terminally ubiquitinated UBE2W as in Fig 7A (62, 63). 
Discussion 
Trypanosomatids are amongst the most ancient of eukaryotes and possess some highly 
divergent biochemistry, for example compartmentalisation of the glycolytic pathway or mRNA 
trans-splicing (64, 65). Despite this, our bioinformatic analysis of the L. mexicana genome 
revealed numerous ubiquitin conjugation system components: 2 ubiquitin E1, 13 ubiquitin E2 
and 79 E3 ligase genes, including 12 HECT E3s, 1 RBR E3, 5 U-box RING E3s, 57 RING and 
4 RING-CH-type E3s. These numbers are similar to those of another single-celled eukaryote, 
S. cerevisiae, which has 1 E1, 11 E2s and 60-100 E3s, of which 5 are HECT E3s, 2 are RBR 
E3s, 2 are U-box E3s, one is a RING CH-type E3 and the rest are RING E3s (66, 67). In 
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contrast, humans have 2 E1s, 40 E2s and over 600 E3s, of which 28 are HECT E3s, around 
15 are RBR E3s, 9 are U-box E3s, 11 are RING CH-type E3s and the rest are RING E3s (67-
71). We also identified a putative SUMO E1 catalytic subunit (UBA2), a Nedd8 E1 catalytic 
subunit (UBA3), a SUMO E2 (UBC9) and a Nedd8 E2 (UBC12), although E1, E2 and E3 
genes for Ubls were not extensively searched for. Despite this, previous characterisation of 
the T. brucei orthologues of UBA2 and UBC9 by in vitro SUMOylation assays and UBA3 and 
UBC12 by affinity purification of Nedd8 lend further weight to their proposed functions (21, 
23). Of the putative ubiquitin E2s identified, 5 were missing the conserved asparagine residue 
thought to be important for E2 catalysis (30-32). UEV1, which also lacks the catalytic cysteine 
residue, is part of the non-catalytic ubiquitin E2 variant protein family. For UBC3, UBC6, 
UBC11 and UBC14, in contrast, the missing asparagine residue may indicate non-canonical 
methods of E2 catalysis. 
Previous work has underscored the importance of the ubiquitination system in Leishmania by 
demonstrating both the essentiality of the parasite proteasome and a key role for DUBs in the 
life cycle of this parasite (8, 15). Our generation of a select ubiquitination gene null mutant 
library revealed that 1 out of 2 ubiquitin E1s and 4 out of 13 ubiquitin E2s could not be deleted 
and therefore may be essential in promastigotes. A smaller proportion (4 out of 20) cysteine 
peptidase DUBs were shown to be essential in promastigotes, perhaps due to a greater 
degree of redundancy in DUB function (8). UBC12, a putative Nedd8 E2, also appears to be 
essential in promastigotes, suggesting it functions independently of the Nedd8 E1 UBA3, 
which is non-essential in promastigotes. This could be due to the presence of an additional 
Nedd8 E1 or a Neddylation-independent function of UBC12. In contrast, none of the HECT or 
RBR E3 ligases were essential in promastigotes, likely attributable to the considerable 
functional redundancy that characterises E3 ligases (72).  
When interpreting our bar-seq data, we reasoned that since null mutants were more likely to 
exhibit decreases in proportional representation as the experiments progressed, our analysis 
should be limited to the identification of loss-of-fitness phenotypes. This is because decreases 
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in the relative abundance of a subset of null mutant lines in the population would lead to an 
increase in the proportional representation of the remaining null mutant lines, potentially 
mimicking gain-of-fitness phenotypes. Despite this limitation, the bar-seq approach allowed 
us to identify numerous fitness phenotypes associated with the promastigote and amastigote 
life cycle stages. In particular, loss-of-fitness was identified for more than one interval between 
SURPDVWLJRWHWLPHSRLQWVIRUǻubc9, hinting at a role for SUMOylation (UBC9), and ǻKHFWand 
ǻKHFW, for HECT E3-mediated ubiquitination, in promastigote growth and/or survival. These 
genes were not absolutely required for survival, however, given our ability to detect ǻubc9, 
ǻhect2 DQGǻhect12 in the metacyclic promastigote samples. Also of interest was the high 
degree of correlation between the data from the axenic amastigote, macrophage and mouse 
infection experiments, supporting previous findings that only small transcriptomic differences 
exist between axenic and intracellular amastigotes (3). The strong phenotypes observed for 
ǻubc1/cdc34ǻubc2ǻuev1 DQGǻhect2 in the amastigote stages suggest an important role 
for these genes in the successful transformation from promastigote to amastigote. Since 
ǻhect2 also showed loss-of-fitness in the promastigote stage, the effect of HECT2 deletion on 
cell survival/proliferation may be a more general one. For example, if the function of human 
UBE3C is shared with HECT2, then the build-up of harmful, incompletely-degraded 
proteasome substrates during the differentiation process could explain the requirement for 
HECT2 in amastigotes and the more subtle effect of HECT2 deletion on promastigotes (35). 
Notably, the observed requirement for UBC1/CDC34 during L. mexicana mouse infection 
mirrors the finding that TbCDC34 is required for infection of mice with bloodstream form T. 
brucei (27). Additionally, the human orthologues of both UBC2 and UEV1 (UBE2N and 
UBE2V1 respectively) have been implicated in the differentiation of various human cell types, 
perhaps pointing to a general role for these protein families in differentiation processes (29, 
73-75). Since both ubiquitination and deubiquitination enzymes have been found to be 
essential in the promastigote to amastigote transition, interplay between the activities of 
E2/E3s (UBC1/CDC34, UBC2, UEV1 and HECT2) and DUBs (DUB4, DUB7 and DUB13) 
could be crucial for maintaining an optimal abundance and/or state of modification of protein 
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targets that are required for differentiation. ǻuba1bǻubc14ǻhect7 DQGǻhect11 were lost at 
later stages DQGǻubc9 showed cumulative loss throughout the experiments, suggesting that 
the deleted genes are required for normal amastigote proliferation, including during mouse 
infection.  
Our finding that UBC2 and UEV1 are highly conserved at both the sequence and structural 
level suggests that their function may be shared between distantly related species. For 
example, that UEV1 is more similar in sequence to HsUBE2V2 and ScMMS2 than to 
HsUBE2V1 hints at a possible function in DNA damage repair (39). Our observation that UBC2 
and UEV1 form a heterodimer was not unexpected and is consistent with the similar 
SKHQRW\SHVREVHUYHGIRUǻubc2 DQGǻuev1 in promastigote to amastigote differentiation. We 
also found that UBC2 is a monomer in vitro. This property is similar to HsUBE2N but contrasts 
with ScUbc13, which is a homodimer in vitro (44). Given that dimerisation does not affect 
ubiquitin transfer by another human E2, UBE2W, this difference may not be physiologically 
relevant (76). Our X-ray crystal structure of the UBC2-UEV1 heterodimer revealed high 
conservation of the UBC2 active site and UBC2-UEV1 interface, highlighting the importance 
of stable UBC2-UEV1 interaction in the function of this complex across diverse eukaryotes.  
Subsequent biochemical characterisation of UBC2 and UEV1 revealed that UBA1a and UBC2 
are a functional ubiquitin E1-E2 pair. This demonstrates a level of specificity for E1-E2 
interactions in L. mexicana, despite both UBA1a and UBA1b being more closely related to 
HsUBA1 than HsUBA6. That UBA1a and UBA1b appear to have unique functions is 
interesting since there is no obvious requirement for two ubiquitin E1s in other single-celled 
eukaryotes. S. cerevisiae, for example, has only one ubiquitin E1. A differential requirement 
for UBA1a and UBA1b is further supported by the likelihood that UBA1a, but not UBA1b, is an 
essential gene in promastigotes.  
The UBC2-UEV1 heterodimer, like its S. cerevisiae and human orthologues, is able to form 
K63-linked ubiquitin chains in vitro, suggesting a role for non-degradative ubiquitin 
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modifications in Leishmania differentiation (30, 39, 44, 45, 48). Most of the chains observed 
in our in vitro assays were di-ubiquitin, supporting our suggestion that UEV1 is more similar to 
human UBE2V2, which forms di-ubiquitin in vitro, than UEV-1A (isoform 2 of UBE2V1), which 
forms polyubiquitin chains (39). Furthermore, our structural modelling of UBC2-UEV1 in 
complex with donor and acceptor ubiquitins, together with the conservation of key UEV1 
residues that are required for acceptor ubiquitin interaction, are consistent with a role for UEV1 
in dictating K63-linked chain specificity by correctly orienting the acceptor ubiquitin (50). In 
contrast, the donor ubiquitin is thought to exhibit flexible positioning around the covalent Cys85 
linkage (50, 77). The physiological role of ubiquitin chains generated by Leishmania UBC2-
UEV1 is currently unknown and an important area for further investigation. However, previous 
research has shown that free ubiquitin chains are present in both S. cerevisiae and human 
cells and that their levels (in S. cerevisiae) increase following heat shock, DNA damage or 
oxidative stress (78). Furthermore, unanchored K63-linked chains generated by the human 
E3 ligases TRAF6 and TRIM32 have been shown to interact with and activate protein kinases 
(79, 80) and unanchored K48-linked chains can inhibit the proteasome (81), demonstrating 
that free ubiquitin chains can perform regulatory functions. Curiously, S. cerevisiae HUL5, the 
E3 ligase partly responsible for free chain formation upon stress induction (78), is related to L. 
mexicana HECT2 (45% query cover, 32.6% identity, E value: 5e-47). This raises the possibility 
that HECT2 is involved in the response to environmental stresses that trigger the promastigote 
to amastigote transition and may explain the requirement for HECT2 in amastigotes. Exploring 
the potential interaction between UBC2-UEV1 or HECT2 and protein kinases involved in 
stress responses is an interesting avenue for further study. Additionally, the identification of 
UBC2 and UEV1 in an interactome of L. mexicana DUB2, which is able to cleave K63-linked 
diubiquitin in vitro, suggests a possible interplay between these proteins in the regulation of 
K63-linked ubiquitin chains (8). 
For our in vitro experiments, human BIRC2 and RNF8 provided useful tools for examining the 
activity of UBC2 in the absence of available Leishmania E3s. Both BIRC2 and RNF8 were 
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able to form polyubiquitin chains (non-K63-linked) in a UBC2-dependent manner. Intriguingly, 
UEV1 effectively inhibited this reaction by switching UBC2 activity towards unanchored K63-
linked di-ubiquitin formation. This ability of UEV1 could allow UBC2 to flip between direct 
(covalent attachment of ubiquitin to substrates) and indirect (unanchored ubiquitin chain 
binding to regulated proteins) mechanisms of regulating other proteins as well as between 
sets of protein targets, depending on the availability of UEV1. The proposed role for UEV1 in 
specifying K63-linked chain formation is further supported by the observation that polyubiquitin 
chains produced in the presence of UBC2 and BIRC2 or RNF8 are not K63-linked. In support 
of our finding that UBC2 acts alone with RNF8, human UBE2V1 and UBE2V2 have been 
shown to be dispensable for the function of UBE2N and RNF8 in DNA damage signalling (82). 
Conversely, the formation of polyubiquitin chains on human CHIP was seen in the presence 
of both UBC2 and UEV1. In this example, K63-linked ubiquitin chains could be formed in a 
RING-dependent manner similar to that described for rat RNF4, where the RING domain 
stabilises the positions of human UBE2N holds the donor ubiquitin LQ D µIROGHG-EDFN¶
conformation poised for nucleophilic attack by K63 of the acceptor ubiquitin bound to UBE2V2 
(77). The ability of UBC2-UEV1 to extend ubiquitin chains on CHIP illustrates the potential for 
UBC2-UEV1 to act in coordination with other E2s in L. mexicana, although an E2 with such a 
role has yet to be identified.  
Previous studies have investigated the importance of DUBs and the parasite proteasome at 
various stages of the Leishmania life cycle (8, 15). Supplementing this, our study explores the 
requirement for selected E1, E2 and E3 enzymes across the life cycle of Leishmania. Our 
detailed investigation of UBC2 and UEV1, identified as essential in amastigotes, demonstrates 
high levels of conservation at both the structural and functional level. Consequently, our finding 
that the nature of UBC2 activity can be regulated by UEV1 has implications for orthologous 
proteins in other species.  
Materials and Methods 
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Bioinformatic identification of ubiquitination genes 
Ubiquitin E1-activating enzyme, E2-conjugating enzyme and E3 ligase genes were identified 
in the L. mexicana genome by performing Interpro and PFAM domain searches in TriTrypDB 
(https://tritrypdb.org/tritrypdb/). The following Interpro and PFAM identification codes were 
used: IPR018075, PF10585, IPR019572, IPR028077, IPR000608, IPR000569, PF00632, 
IPR002867, PF01485, IPR001841, IPR011016, IPR003613 and PF04564. UniProt 
(https://www.uniprot.org/) was also XVHGWRVHDUFKIRUJHQHVDQQRWDWHGZLWKWKHWHUPV³+(&7´
RU ³5%5´ 3URWHLQ %/$67 VHDUFKHV ZHUH XVHG WR GHWHUPLQH WKH SHUFHQWDJe query cover, 
percentage identity and E value for two gene sequences. 
Leishmania culture 
L. mexicana (MNYC/BZ/62/M379) promastigotes were grown in HOMEM (Gibco) 
supplemented with 10% v/v heat-inactivated Fetal Bovine Serum (FBS) (Gibco) and 1% v/v 
Penicillin/Streptomycin (Sigma-Aldrich) at 25°C. Typically, cells were split around twice a 
week. Selection drugs were added to the medium as appropriate: 10 µg mL-1 blasticidin 
(InvivoGen), 40 µg mL-1 puromycin (InvivoGen), 10-15 µg mL-1 G418 (InvivoGen), 50 µg mL-1 
hygromycin (InvivoGen) and 50 µg mL-1 nourseothricin (Jena Bioscience). 
Null mutant library generation 
Null mutants were generated using the CRISPR-Cas9-based approach as previously 
described (8, 33). Primer sequences to allow amplification of the single guide DNAs (sgDNAs) 
and repair cassettes for gene deletion were designed by entering the relevant gene identifiers 
into an automated web tool (http://www.leishgedit.net/Home.html). Primers for amplification of 
the repair cassettes contained primer binding sites for pTBlast_v1, pTPuro_v1 or pTNeo_v1 
plasmids (sequences available from leishgedit.net) and 30 nt homology arms to allow 
recombination (83). Additionally, a T7 polymerase promoter sequence, 10 nt linker and 12 nt 
XQLTXHEDUFRGHZHUHLQVHUWHGLQWRWKH¶HQGRIWKHXSVWUHDPIRUZDUGSULPHULQWKHIROORZLQJ
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RUGHU¶-TAATACGACTCACTATAAAACTGGAAGXXXXXXXXXXXX-¶ZKHUH;UHSUHVHQWV 
the barcoded region. 
PCR reactions for cassette amplification contained 30 ng of plasmid (pTBlast_v1, pTPuro_v1 
or pTNeo_v1), 0.2 mM dNTPs, 2 µM each of forward and reverse primer, 1U Q5 DNA 
Polymerase (NEB), 1x Q5 reaction buffer (NEB) and distilled water to make the volume up to 
40 µL. The reverse primer used for generating all guides was 
aaaagcaccgactcggtgccactttttcaagttgataacggactagccttattttaacttgctatttctagctctaaaac. The PCR 
was run with the following settings: 94°C for 5 min, 45 cycles of 94°C f or 30 s, 65°C for 30 s 
and 72°C for 2 min 15 s and 72°C for 7 min. For the sgRNAs, PCR reactions were set up in a 
similar manner but with a total volume of 20 µL. The PCR program used was 98°C for 30 s, 
35 cycles of 98°C for 10 s, 60°C for 30 s and 72°C for 15 s and 72°C for 10 min. 
Mid-log phase L. mexicana Cas9 T7 procyclic promastigotes were transfected either with 
whole PCR reactions (120 µL total volume) or 2.5 µg of DNA purified from PCR reactions 
using the QIAquick PCR Purification Kit (Qiagen). 8 x 106 log phase cells were prepared by 
spinning down (1,000 x g for 10 min), washing with 1 x PBS and resuspending in 1 x Cytomix 
(66.7 mM Na2HPO4, 23.3 mM NaH2PO4, 5 mM KCl, 50 mM HEPES and 150 µM CaCl2, pH 
7.3) or P3 solution from the P3 Primary Cell 4D-Nucleofector X Kit (Lonza). Next, cells were 
pulsed twice using the Nucleofector 2B device (Lonza) and the X-001 program or using the 
Amaxa 4D-Nucleofector (Lonza) and the FI-115 programme (for the Cytomix and P3 solutions 
respectively) and then placed into 5 mL of HOMEM media with 20% FBS and 1% 
Penicillin/Streptomycin. As a negative control, the parental cell line was transfected with water 
in place of DNA.  
Following recovery of the cells at 25°C, appropriate antibiotics were added (10 µg mL- 1 
blasticidin, 40 µg mL-1 puromycin, 15 µg mL-1 G418) to select for transfectants. Selection 
was performed either on a population level (10 mL containing the total transfected population) 
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or along with cloning into 96-well plates at 1:6, 1:66 and 1:726 dilutions. Dilutions were carried 
out in HOMEM supplemented with 20% v/v FBS and 1% v/v Penicillin/Streptomycin. 
To extract genomic DNA for analysis, 500 µL-5 mL of mid-log phase promastigotes were 
centrifuged (1,000 x g for 10 min), washed once in 1 x PBS and processed using the Qiagen 
DNeasy Blood and Tissue KLWDQGWKHPDQXIDFWXUHU¶VSURWRFRO)RUJHQRW\SHDQDO\VLV3&5
UHDFWLRQVZHUHVHWXSZLWKȝ/RIgenomic DNA and either Q5 DNA Polymerase (NEB) or 
/RQJ$PS7DT1(%ZLWKWKHPDQXIDFWXUHU¶VSURWRFROV 
Bar-seq screen 
The bar-seq screen was performed as described previously in Damianou et al., 2020 (8); the 
raw data are available in S4 Table. Statistical analyses were performed between adjacent 
experimental time points using paired t-tests and the Holm-âtGiN method in GraphPad Prism 
8. 
Cell viability assay 
L. mexicana cultures were grown to stationary phase (>1 x 107 mL-1) and resuspended at 1 x 
106 FHOOVSHUP/LQDPDVWLJRWHPHGLXP6FKQHLGHU¶V'URVRSKLODPHGLXP>*LEFR@)%6
[Gibco] and 15 µg mL-1 HEMIN [Sigma], adjusted to pH 5.5). 200 µL cell samples were 
prepared in sextuplicate in 96-well plates and included the parental cell line (Cas9 T7) as a 
positive control. Also included were media-only, negative control samples. At 0 h, 48 h and 
120 h, 20 µL of 125 µgmL-1 resazurin (in 1 x PBS) was added to sample wells and the plate 
incubated at 37°C for 8 h. The fluorescence at 590 nm was then read using the POLARst ar 
Omega Plate Reader (BMG Labtech). Relative viability was calculated for each sample by 
averaging fluorescence readings across the 6 replicates, subtracting the average for the 
negative control and then dividing by the value obtained for the Cas9 T7 positive control. 
Sequence alignments 
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S. cerevisiae sequences were obtained from UniProtKB (84), human sequences from 
UniProtKB or NCBI and L. mexicana and T. brucei sequences from TriTrypDB (85). Sequence 
alignments were performed using T-Coffee (86) and structural annotation using ESPript 3.0 
(87). 
Protein expression and purification 
UBA1a (LmxM.23.0550), UBC2 (LmxM.04.0680) and UEV1 (LmxM.13.1580) genes were 
codon-optimised for E. coli expression and synthesised by DC Biosciences. Genes were 
amplified by PCR and inserted into an expression vector (Protein Production Facility, 
University of York) in frame with an N-terminal His tag and Im9 solubility tag (40) using In-
Fusion cloning (Takara). Primers used for gene DPSOLILFDWLRQ ZHUH ¶-
TCCAGGGACCAGCAATGCTTTCTGAGGAAGAGCAAAAAC-¶ DQG ¶-
TGAGGAGAAGGCGCGTTAAAAGCGATAGCGGTAGCGGATG-¶ IRU 8%$D ¶-
TCCAGGGACCAGCAATGTTGACCACTCGTATCATTAAGG-¶ DQG
TGAGGAGAAGGCGCGTCATGGTTTGGCGTACTTACGAG-¶ IRU 8%& DQG ¶-
TCCAGGGACCAGCAATGGTCGAGGTTCCGCGC-¶ DQG ¶-
TGAGGAGAAGGCGCGTCAGTAGGTACTACCCTCC-¶ for UEV1. Insert integration and 
sequence were confirmed by DNA sequencing (Eurofins). Plasmids were then transformed 
into BL21-Gold (DE3) cells (Agilent Technologies). Cells were grown overnight in 5 mL of LB 
medium with 25 µgmL-1 kanamycin and used to seed 500 mL cultures for growth at 37°C. 
When an optical density of around 0.5 at 600 nm was reached, cultures were equilibrated to 
20°C and 1 mM of isopropyl 1-thio- ȕ-D-galactopyranoside was added to induce recombinant 
protein production. Cultures were then grown for a further 24 h at 20°C. 
The standard purification procedure was as follows: bacterial pellets from 500 mL cultures 
were resuspended in 25 mL buffer A (20 mM NaH2PO4·2H2O, 20 mM Na2HPO4·12H2O, 0.3 M 
1D&O  P0 LPLGD]ROH DQG  P0 ȕ-mercaptoethanol, pH 7.4), DNase-treated and 
homogenised using a cell disruptor (Constant Systems Ltd). The lysate was centrifuged 
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(35,000 x g, 10 min, 4°C), filtered and loaded onto a HisTrap Fast Flow Crude column (G E 
Healthcare). After column washes with buffer A, a gradient of buffer B (20 mM NaH2PO4·2H2O, 
20 mM Na2HPO4·12H2O, 0.3 M 1D&O0LPLGD]ROHDQGP0ȕ-mercaptoethanol, pH 7.4) 
was applied to elute bound protein. His-Im9 tag cleavage was then carried out using at least 
one tenth HRV 3C protease (Protein Production Facility, University of York) to sample protein 
(mg). This was followed by imidazole removal using either overnight dialysis at 4°C in buffer 
C (20 mM NaH2PO4·2H2O, 20 mM Na2HPO4·12H22  0 1D&O DQG  P0 ȕ-
mercaptoethanol, pH 7.4) or a desalt column. Removal of the His-Im9 tag leaves an additional 
3 amino acids (Gly, Pro, Ala) at the N-terminus. Following cleavage, the sample was reapplied 
to the HisTrap column and application of buffer A and B used to separate the tag from the 
protein of interest. Sample fractions were concentrated and size-exclusion chromatography 
(SEC) carried out using HiLoad 16/600 Superdex 200 preparation grade (pg) or 75 pg columns 
(GE Healthcare) for UBA1a and UBC2 or UEV1 respectively. Buffer used for SEC contained 
50 mM HEPES and 150 mM NaCl with either 2 mM DTT (UBC2 and UEV1) or 1 mM TCEP 
(UBA1a). Fractions containing purified protein were identified by SDS-PAGE analysis, pooled, 
concentrated and stored at -80°C. 
For the UBC2 and UEV1 samples used for SEC-MALLS, purification was carried out as 
described above but with the following minor changes: buffers A-& GLG QRW FRQWDLQ ȕ-
mercaptoethanol, UBC2 was not purified by SEC and the buffer used for SEC of UEV1 was 
25 mM Tris-HCl, 150 mM NaCl, pH 8. Storage was in the final purification buffers plus 1 mM 
DTT. 
Size-exclusion chromatography multi-angle laser light scattering (SEC-MALLS) 
Prior to loading, mixtures of UBC2 and UEV1 were prepared as required and incubated on ice 
for 30 min. 120 µL of each sample was then loaded onto a Superdex 200 HR10/300 gel 
filtration column (Sigma-Aldrich) and run in 25 mM Tris-HCl, 150 mM NaCl and 1 mM DTT, 
pH 8. Light scattering and refractive index measurements were taken using a Dawn Heleos II 
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and Optilab rEx detector (Wyatt) respectively. Concentrations of samples loaded were 
between 1.2 and 2 mg mL-1. 
Crystallisation and structure determination 
For crystallisation experiments, UBC2 and UEV1 were mixed in a 1:1 molar ratio to a final 
concentration of 6.6 mg mL-1 in buffer containing 50 mM HEPES, 150 mM NaCl and 2 mM 
DTT and incubated on ice for 30 min. Crystallisation conditions  were screened (PACT premier 
HT-96 screen, Molecular Diagnostics) in a 96-well sitting drop format. Drops consisting of 150 
nL of protein and 150 nL of reservoir solution were mixed and incubated above 100 µL of 
reservoir solution. Crystals appeared after two days at 25°C in drops prepared with a rese rvoir 
solution consisting of 0.1 M Bis-Tris propane, pH 7.5, 0.2 M sodium formate and 20% PEG. A 
single crystal was captured in a fine nylon loop, cryo-cooled in liquid nitrogen, and sent for 
data collection at the Diamond Light Source (Beamline I03). The diffraction data, extending to 
a nominal resolution of 1.7 Å, were processed using the 3dii pipeline in xia2 (88). The crystals 
belonged to space group P21 with two UBC2-UEV1 heterodimers in the asymmetric unit. 
The structure was solved by molecular replacement in the program MOLREP (89) 
implemented in the CCP4i2 interface (90). The search model used was the coordinate set for 
the human UBE2N-UBE2V2 complex (PDB ID: 1J7D). Model rebuilding and refinement were 
carried out using iterations of the programs Buccaneer (91) Refmac5 (92, 93) and Coot (94) 
in CCP4i2 (90). The electron density maps were of good quality allowing the confident tracing 
of the protein chains in the two heterodimers (AB and CD) with the exception of residues in 
the D1-E1 loop of UEV1 chains (B and D) where the maps were of poorer quality such that 
residues Gly22 and Ser23 could not be built in Chain D. It is assumed that this region of the 
structure has higher mobility. Data collection and refinement statistics are given in S4 Table. 
The coordinates and structure factors for the L. mexicana UBC2-UEV1 complex are available 
in the Protein Data Bank (PDB ID:6ZM3). 
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Structure analysis 
6XSHUSRVLWLRQ RI VWUXFWXUHV DQG 506' GHWHUPLQDWLRQ ZHUH SHUIRUPHG XVLQJ ³VXSHUSRVe 
VWUXFWXUHV´ LQ CCP4mg (95). UBC2-UEV1 interface analysis was performed using PISA 
(version 1.52) (96). 
Thioester formation assay 
Reactions contained 300 nM UBA1a, 2.5 µM E2, 20 µM human ubiquitin (Boston Biochem) 
and 5 mM ATP as indicated in 40 µL ubiquitination assay buffer (50 mM HEPES, pH 7.5, 100 
mM NaCl, 10 mM MgCl2 and 2 mM DTT). Reactions were incubated for 0-10 min at room 
temperature and then quenched with sample buffer with or without reducing agent. Samples 
containing reducing agent were heated at 90°C for 5 min. Samples were run on an  SDS-PAGE 
gel and stained with InstantBlue Coomassie Protein Stain (Expedeon). For the UBE2W 
thioester assay, bovine ubiquitin (Ubiquigent) was used in place of human ubiquitin. 
Di-ubiquitin formation assay 
Reactions contained 100 nM UBA1a, 2.5 µM of UBC2 and UEV1, 100 µM of human wild-type 
(Boston Biochem) or K63R ubiquitin (2B Scientific) and 5 mM ATP as indicated in 40 µL of 
ubiquitination assay buffer. Samples were incubated at 37°C for between 0 and 90 min as 
indicated. For the inhibitor assay, 0-50 µM of NSC697923 (Abcam) was pre-incubated with 
UBC2 and UEV1 in reaction buffer for 15 min at room temperature prior to addition of UBA1a 
and ATP. The reaction was then incubated at 37°C for 90 min. The final D MSO concentration 
in these reactions was 0.5%. Following incubation, reducing sample buffer was added and the 
samples heated at 90°C for 5 min. Samples were separated by SDS-PAGE and W estern 
blotting carried out using a mouse mono- and polyubiquitinated ubiquitin conjugate 
(Ubiquigent) or mouse Ub-K63 (ThermoFisher) antibody with HRP-conjugated anti-mouse 
secondary antibody (GE Healthcare or Promega). In addition to the experimental samples, 
100 ng of K63 di-ubiquitin positive control (Ubiquigent) was loaded where indicated. 
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E3 cooperation assay 
Reactions were prepared with 100 nM UBA1a, 2.5 µM E2 (UBC2 or UEV1), 1 µM human E3 
(BIRC2, RNF8 or HUWE1), 100 µM ubiquitin (Boston Biochem) and 5 mM ATP as indicated 
in ubiquitination assay buffer in 40 µL total reaction volume. BIRC2, RNF8 and (N-terminally 
truncated) HUWE1 were all GST-tagged and sourced from Ubiquigent. Samples were then 
incubated at 30°C for 1 h prior to SDS-PAGE and Western blotting wit h a mouse mono- and 
polyubiquitinated ubiquitin conjugate (Ubiquigent), mouse Ub-K63 (ThermoFisher) or rabbit 
anti-GST (Abcam) antibody with HRP-conjugated anti-mouse (GE Healthcare) or HRP-
conjugated anti-rabbit (GE Healthcare) secondary antibody as appropriate. 
CHIP priming and extension assay 
Reactions were prepared with 0.1 µM UBA1a, 2.5 µM 6His-tagged UBE2W (Ubiquigent), 1 
µM CHIP (Ubiquigent), 0.1 mM human ubiquitin (Boston Biochem) and 2 mM ATP (Sigma-
Aldrich) in ubiquitination assay buffer in 50 µL total reaction volume. Samples were incubated 
at 30°C for 1 h prior to SDS-PAGE and Western blotting with a mouse mono- and 
polyubiquitinated conjugate (Ubiquigent) or rabbit CHIP antibody (Calbiochem) with HRP-
conjugated anti-mouse (GE Healthcare) or HRP-conjugated anti-rabbit (GE Healthcare) 
secondary antibody as appropriate. 
Supplementary methods 
Thioester formation assay 
Reactions contained 6 pmol E1 (UBA1a or UBA1b), 2.5 µM E2 (UBC2 or UEV1), 2 nmol 
human ubiquitin (Boston Biochem) and 2 mM ATP as indicated in 20 µL ubiquitination assay 
buffer. Reactions were incubated for 30 min at 30°C. Sample buffer with or without reducing 
agent was then added and the samples containing reducing agent heated at 90°C for 5 min. 
Samples were run on an SDS-PAGE gel and stained with InstantBlue Coomassie Protein 
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Stain (Expedeon). Recombinant L. mexicana UBA1b was donated by Daniel Harris, University 
of Glasgow. 
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Figure 1. Life cycle phenotyping of ubiquitination gene null mutants. Fifty-eight null mutant 
lines were pooled (n = 6) as procyclic promastigotes and grown to stationary phase. Cells 
were then induced to differentiate into axenic amastigotes in vitro or metacyclic promastigotes 
purified and used to infect macrophages or mice. A Experimental workflow showing the time 
points at which DNA was extracted for barcode amplification and next generation sequencing. 
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The heat maps for promastigote to B axenic amastigote, C macrophage infection or D mouse 
infection experiments show the average proportional representation of each null mutant at 
each experimental time point, calculated by dividing the number of reads for null mutant-
specific barcodes by the total number of reads for expected barcodes. Samples included 
represent promastigote time-point zero (PRO 0 h), early-log phase (PRO 24 h), mid-log phase 
(PRO 48 h), late-log phase (PRO 72 h), stationary phase (PRO 168 h), early axenic 
amastigote differentiation (AXA 24 h), post-axenic amastigote differentiation (AXA 120 h), 
purified metacyclic promastigotes (META), early macrophage infection (inMAC 12 h), late 
macrophage infection (inMAC 72 h), 3 week footpad mouse infection (FP 3) and 6 week 
footpad mouse infection (FP 6). 
39 
 
 
Figure 2. Alignments of LmUBC2 and LmUEV1 with selected orthologues. Sequence 
alignment and structural annotation were performed using T-Coffee and ESPript 3.0 
respectively for A LmUBC2 and B LmUEV1. Red boxes indicate amino acid identity, red 
characters show similarity within the highlighted group and blue frames highlight similarity 
across groups. Positions of the UBC2 HPN motif and catalytic cysteine are shown by a black 
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line and triangle respectively. Secondary structures derived from the crystallised L. mexicana 
UBC2-UEV1 heterodimer (Fig 4) are represented above the sequence alignment with helices 
represented by spirals and beta sheets by arrows. Asterisks denote important interface 
residues in the L. mexicana complex. Lm, Leishmania mexicana; Tb, Trypanosoma brucei; 
Sc, Saccharomyces cerevisiae; Hs, Homo sapiens. 
 
Figure 3. UBC2 and UEV1 form a stable heterodimer in vitro. A SDS-PAGE gel showing 
recombinant UBA1a, UBC2 and UEV1 stained with InstantBlue stain. Proteins were 
expressed in E. coli and purified by nickel affinity and size-exclusion chromatography. 1 µg of 
each protein was loaded onto the gel. B Elution profiles of UBC2, UEV1 and a 1:1 molar mix 
of UBC2-UEV1 presented as changes in refractive index over time. Curved lines show 
changes in refractive index for UBC2-UEV1 (black), UBC2 (red) and UEV1 (blue). The 
expected mass (as estimated from light scattering data) in kDa is indicated by a dashed line 
above the peak corresponding to each protein sample. 
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Figure 4. Structure of the UBC2-UEV1 heterodimer. A Ribbon diagram showing the crystal 
structure of UBC2 (green) and UEV1 (blue) in complex. The location of the N- and C-termini 
DUHKLJKOLJKWHGDORQJZLWKWKHQXPEHULQJRIDOSKDKHOLFHVĮ and beta strands ȕB Zoom-in 
of the conserved catalytic residues in UBC2. The HPN motif and proposed catalytic cysteine 
are shown as cylinders coloured by atom (red, oxygen; blue, nitrogen; yellow, sulfur). C-D 
Zoom-in of interface between UBC2 and UEV1 with UBC2 or UEV1 as a surface fill model 
respectively. Amino acid residues are shown as cylinders coloured by atom (red, oxygen; blue, 
nitrogen). Hydrogen bonds are denoted by dashed lines. 
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Figure 5. UBA1a and UBC2 cooperate in ubiquitin transfer in vitro. A Thioester assay 
demonstrating the ability of UBA1a and UBC2 to form thioester bonds with ubiquitin. UBA1a, 
ubiquitin and ATP were incubated with UBC2 and UEV1 as indicated in ubiquitination assay 
buffer for up to 10 min at room temperature. Samples were treated with either reducing or non-
reducing sample buffer and visualised by SDS-PAGE with InstantBlue stain. B Di-ubiquitin 
formation assay. UBA1a, ubiquitin and ATP were incubated with UBC2 and UEV1 as indicated 
in ubiquitination assay buffer for up to 90 min at 37°C. Reactions we re then treated with 
reducing sample buffer and visualised by immunoblotting with either ubiquitin conjugate or 
K63-linked ubiquitin antibodies. C Di-ubiquitin formation assay performed as for B but with 
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wild-type ubiquitin substituted for K63R ubiquitin where shown. D UBC2 and UEV1 were pre-
incubated with UBE2N inhibitor NSC697923 as indicated for 15 min prior to setting up a di-
ubiquitin formation assay as in B. For C and D, samples were treated with reducing sample 
buffer prior to SDS-PAGE and immunoblotting with ubiquitin conjugate antibody. Data shown 
in A-D are representative. No 2/V1, no UBC2 or UEV1. E Schematic summarising the findings 
of A-D. UBA1a activates ubiquitin in an ATP-dependent manner, allowing ubiquitin to bind to 
the active site of UBA1a via a thioester linkage. Ubiquitin is then transferred to UBC2 (green) 
which, when present in complex with UEV1 (yellow), can generate free K63-linked ubiquitin 
chains. 
 
Figure 6. Cooperation of UBC2 with human E3s in in vitro polyubiquitination. A UBA1a, 
ubiquitin and ATP were incubated with UBC2, UEV1 and human E3s (BIRC2, RNF8 and 
HUWE1) as indicated in ubiquitination assay buffer for 1 h at 30°C. Reaction s were visualised 
by immunoblotting with either ubiquitin conjugate, K63-linked ubiquitin or GST antibodies as 
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shown. 2, UBC2; V1, UEV1; -, no UBC2 or UEV1; no E3, no BIRC2, RNF8 or HUWE1. B 
Schematic summarising the findings of A. UBA1a activates ubiquitin in an ATP-dependent 
manner, allowing ubiquitin to bind to the active site of UBA1a via a thioester linkage. Ubiquitin 
is then transferred to UBC2 which can, by interacting with the human E3s BIRC2 and RNF8, 
form non-K63-linked polyubiquitin chains. UEV1 inhibits this association, presumably via its 
interaction with UBC2. 
 
Figure 7. Ubiquitin chain extension activity of UBC2-UEV1. A Thioester assay showing 
ubiquitin transfer to UBE2W from both human UBA1 and L. mexicana UBA1a. UBE2W, 
ubiquitin and ATP were incubated with human UBA1 or L. mexicana UBA1a as indicated in 
ubiquitination assay buffer for up to 10 min at room temperature. Samples were treated with 
either reducing or non-reducing sample buffer and visualised by SDS-PAGE with InstantBlue 
stain. B UBA1a, ubiquitin and ATP were incubated with UBC2, UEV1, human UBE2W and 
human CHIP as indicated in ubiquitination assay buffer for 1 h at 30°C.  Reactions were 
visualised by immunoblotting with either ubiquitin conjugate or CHIP antibodies as shown. C 
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Schematic summarising A-B. UBA1a activates ubiquitin in an ATP-dependent manner, 
allowing ubiquitin to bind to the active site of UBA1a via a thioester linkage. Ubiquitin is then 
transferred to HsUBE2W which monoubiquitinates HsCHIP. Alternatively, HsUBE2W can 
ubiquitinate its own N-terminus. Once primed with monoubiquitin, UBC2-UEV1 can extend 
ubiquitin chains on HsCHIP. Lm, Leishmania mexicana; Hs, Homo sapiens. Where species is 
not indicated, proteins are from L. mexicana. 
S1 Table. Summary of L. mexicana ubiquitination genes.  
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Gene name Type L. mexicana gene ID Size (kDa) T. brucei orthologue 
UBA1a Ubiquitin E1 LmxM.23.0550 115.1 Tb927.8.2640 
UBA1b Ubiquitin E1 LmxM.34.3060 126.7 Tb11.v5.0675, Tb927.9.12650 
UBA2 SUMO E1 LmxM.08.0220 109.7 Tb927.5.3430 
UBA3 Nedd8 E1 LmxM.01.0710 56.1 Tb927.9.4620 
UBC1/CDC34 Ubiquitin E2 LmxM.31.0960 30 Tb11.01.5790 
UBC2 Ubiquitin E2 LmxM.04.0680 17.1 Tb927.9.8000 
UBC3 Ubiquitin E2 LmxM.05.0930 48.8 Tb927.7.6960 
UBC4/PEX4 Ubiquitin E2 LmxM.07.0850 20 Tb927.8.920 
UBC5 Ubiquitin E2 LmxM.22.0610 28.2 Tb927.7.2540 
UBC6 Ubiquitin E2 LmxM.33.1555 18.4 Tb927.4.2710 
UBC7 Ubiquitin E2 LmxM.24.2130 17 Tb927.8.6090 
UBC8 Ubiquitin E2 LmxM.31.0700 26.3 Tb927.11.13940 
UBC9 SUMO E2 LmxM.02.0390 17.1 Tb927.2.2460 
UBC10 Ubiquitin E2 LmxM.32.2770 26.1 Tb927.2.3720 
UBC11 Ubiquitin E2 LmxM.33.0900 31.7 Tb927.4.3190, Tb927.4.3460 
UBC12 Nedd8 E2 LmxM.24.1710 21.6 Tb927.8.6510 
UBC13 Ubiquitin E2 LmxM.34.1300 16.7 Tb927.5.1000 
UBC14 Ubiquitin E2 LmxM.24.2140 36.4 Not identified 
UEV1 Ubiquitin E2 variant LmxM.13.1580 16 Tb927.11.3310 
HECT1 HECT E3 ligase LmxM.36.6340 455.4 Tb927.10.8390 
HECT2 HECT E3 ligase LmxM.29.0910 153 Tb927.6.2370 
HECT3 HECT E3 ligase LmxM.07.0280 666.2 Tb927.8.1590 
HECT4 HECT E3 ligase LmxM.13.1470 592.1 Tb927.11.3390 
HECT5 HECT E3 ligase LmxM.36.4370 276.8 Tb11.v5.0817, Tb927.10.9750 
HECT6 HECT E3 ligase LmxM.26.2370 421.9 Tb927.9.1770 
HECT7 HECT E3 ligase LmxM.31.1090 178.7 Tb927.11.14330 
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HECT8 HECT E3 ligase LmxM.31.3930 453.9 Tb927.11.16260 
HECT9 HECT E3 ligase LmxM.33.3960 149.3 Tb927.4.770 
HECT10 HECT E3 ligase LmxM.34.2450 250.9 Tb927.9.13360 
HECT11 HECT E3 ligase LmxM.34.5390 732.6 Tb927.4.310 
HECT12 HECT E3 ligase LmxM.34.4000 147.1 Not identified 
HECT13 HECT E3 ligase LmxM.33.3400 36.3 Not identified 
HECT14 HECT E3 ligase LmxM.26.2650 63.5 Tb927.9.1350 
RBR1 RBR E3 ligase LmxM.29.2170 58.1 Tb927.6.3780 
Not given RING-type zinc finger-containing LmxM.15.1410 52.8 Tb927.9.5260 
Not given RING-type zinc finger-containing LmxM.21.0023 12.2 Tb927.10.1810 
Not given RING-type zinc finger-containing LmxM.24.1610 13.1 Not identified 
Not given RING-type zinc finger-containing LmxM.34.0660 133.9 Tb927.10.3800 
Not given RING-type zinc finger-containing LmxM.34.4500 9.4 Tb927.9.10170 
Not given RING-type zinc finger-containing LmxM.01.0430 81.2 Tb927.9.4050 
Not given RING-type zinc finger-containing LmxM.02.0140 94.1 Tb927.2.2360 
Not given RING-type zinc finger-containing LmxM.03.0010 104.9 Not identified 
Not given RING-type zinc finger-containing LmxM.04.0540 63.7 Not identified 
Not given RING-type zinc finger-containing LmxM.04.0640 35.7 Not identified 
Not given RING-type zinc finger-containing LmxM.07.0370 96.5 Not identified 
Not given RING-type zinc finger-containing LmxM.08.1091 41.1 Tb927.5.2920 
Not given RING-type zinc finger-containing LmxM.08.1215 56.3 Tb927.5.3070 
Not given RING-type zinc finger-containing LmxM.09.0140 57.3 Tb927.11.12190 
Not given RING-type zinc finger-containing LmxM.09.0350 88.4 Not identified 
Not given RING-type zinc finger-containing LmxM.09.0430 51.9 Tb927.11.12440 
Not given RING-type zinc finger-containing LmxM.09.1210 44.9 Not identified 
Not given RING-type zinc finger-containing LmxM.10.0440 17.6 Not identified 
Not given RING-type zinc finger-containing LmxM.10.1140 39.3 Tb927.8.4570 
Not given RING-type zinc finger-containing LmxM.12.0100 32 Tb927.6.1190 
Not given RING-type zinc finger-containing LmxM.12.1240 96 Tb927.1.4520 
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Not given RING-type zinc finger-containing LmxM.25.0740 122.7 Tb927.11.750 
Not given RING-type zinc finger-containing LmxM.25.2230 38 Tb11.v5.0818, Tb927.3.2340 
Not given RING-type zinc finger-containing LmxM.25.2290 33.2 Tb927.3.2410 
Not given RING-type zinc finger-containing LmxM.26.1170 55.2 Tb927.7.770 
Not given RING-type zinc finger-containing LmxM.26.1560 204.2 Tb927.7.1090 
Not given RING-type zinc finger-containing LmxM.27.0570 59.9 Tb11.v5.0388, Tb927.11.1190 
Not given RING-type zinc finger-containing LmxM.27.1200 44.1 Tb11.1410, Tb927.11.1810 
Not given RING-type zinc finger-containing LmxM.28.0760 83 Tb927.11.8010 
Not given RING-type zinc finger-containing LmxM.28.1300 45.9 Tb927.5.4280 
Not given RING-type zinc finger-containing LmxM.28.1830 99.6 Tb927.11.8010 
Not given RING-type zinc finger-containing LmxM.29.1230 78.8 Tb927.6.2710 
Not given RING-type zinc finger-containing LmxM.30.2890 135.3 Tb927.8.7200 
Not given RING-type zinc finger-containing LmxM.31.0560 19.8 Not identified 
Not given RING-type zinc finger-containing LmxM.13.0230 44.9 Tb927.11.4560 
Not given RING-type zinc finger-containing LmxM.16.0650 11.6 Tb927.5.3745 
Not given RING-type zinc finger-containing LmxM.17.0030 21 Tb927.7.6190 
Not given RING-type zinc finger-containing LmxM.17.0290 76.2 Not identified 
Not given RING-type zinc finger-containing LmxM.17.0400 113.6 Not identified 
Not given RING-type zinc finger-containing LmxM.18.1150 39.4 Tb927.10.12940 
Not given RING-type zinc finger-containing LmxM.18.1570 16.9 Tb927.10.12460 
Not given RING-type zinc finger-containing LmxM.19.1150 288.2 Tb11.v5.0394, Tb927.10.15750 
Not given RING-type zinc finger-containing LmxM.36.1930 32.6 Not identified 
Not given RING-type zinc finger-containing LmxM.36.2930 59.4 Not identified 
Not given RING-type zinc finger-containing LmxM.36.3830 34 Tb927.11.9660 
Not given RING-type zinc finger-containing LmxM.21.1295 28.2 Not identified 
Not given RING-type zinc finger-containing LmxM.22.0060 84.8 Tb927.3.5640, Tb927.7.2050 
Not given RING-type zinc finger-containing LmxM.22.0190 50.8 Not identified 
Not given RING-type zinc finger-containing LmxM.23.0280 117.9 Not identified 
4 
 
Not given RING-type zinc finger-containing LmxM.23.1730 42.9 Tb927.8.3460 
Not given RING-type zinc finger-containing LmxM.24.0080 55.3 Tb927.11.4860 
Not given RING-type zinc finger-containing LmxM.24.0300 193.2 Tb927.11.5020 
Not given RING-type zinc finger-containing LmxM.24.1380 44.1 Tb927.8.6850 
Not given RING-type zinc finger-containing LmxM.24.1390 37.3 Tb927.8.6850 
Not given RING-type zinc finger-containing LmxM.25.0340 72 Tb927.3.5390 
Not given RING-type zinc finger-containing LmxM.34.2520 42.8 Tb927.9.13300 
Not given RING-type zinc finger-containing LmxM.29.2360 60.8 Tb927.6.3640 
Not given RING-CH-type zinc finger-
containing LmxM.08_29.1630 135 Tb927.3.4220 
Not given RING-CH-type zinc finger-
containing LmxM.27.0120 70.1 Tb927.3.710 
Not given RING-CH-type zinc finger-
containing LmxM.30.0030 115.9 Not identified 
Not given RING-CH-type zinc finger-
containing LmxM.30.1920 140.1 Tb927.4.4880, Tb927.8.7580 
Not given U-box E3 ligase LmxM.06.0510 71.2 Not identified 
Not given U-box E3 ligase LmxM.13.0660 76 Tb927.11.4210 
Not given U-box E3 ligase LmxM.26.1600 72.8 Not identified 
Not given U-box E3 ligase LmxM.27.2480 53 Tb927.2.5240 
Not given U-box E3 ligase LmxM.08_29.0780 66.8 Tb927.3.3560 
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S2 Table. Summary of primers and plasmids. 
Oligo 
number 
Target/asso
ciated gene Sequence Direction Notes 
OL5674 
BSD 
(blasticidin 
resistance 
gene) GACGATACAAGTCAGGTTG Reverse 
Blasticidin 
resistance 
cassette for 
diagnostic 
PCRs 1 
OL6137 gDNA 
aaaagcaccgactcggtgccactttttcaagttgataacggactagccttattttaacttgctatttctagctctaaa
ac Reverse 
Standard 
primer for 
T7RPol 
expression 
of sgRNA 
(contains 
Cas9 
scaffold for 
generation 
of sgRNA 
PCR) 
OL6367 
LmxM.36.63
40 gaaattaatacgactcactataggACCATTGCTCTCAAAACAAGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6370 
LmxM.29.09
10 gaaattaatacgactcactataggAGTCCTTCGCACAAACACTGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6373 
LmxM.07.02
80 gaaattaatacgactcactataggAAGGGTTCCAATAGTTGGGGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6376 
LmxM.13.14
70 gaaattaatacgactcactataggACACACACACGCCAATAAAAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6379 
LmxM.36.43
70 gaaattaatacgactcactataggTCCATTACACGGCAGCACTGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6382 
LmxM.26.23
70 gaaattaatacgactcactataggAGGACGCAACCAGAGGCAAAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6385 
LmxM.31.10
90 gaaattaatacgactcactataggACTAAGGTGAGGACGTCACAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
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OL6388 
LmxM.31.39
30 gaaattaatacgactcactataggCTTTGGTGCGGTTTCCATCTgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6391 
LmxM.33.39
60 gaaattaatacgactcactataggTTCACAAAGTACTCTGAGGCgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6394 
LmxM.34.24
50 gaaattaatacgactcactataggTACCAAGAGCGAGTACTGTGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6397 
LmxM.34.53
90 gaaattaatacgactcactataggTAACAATAGCGTTTCTACGGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6400 
LmxM.29.21
70 gaaattaatacgactcactataggGCCATTACGACATGGGAAAAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6838 
LmxM.02.03
90 gaaattaatacgactcactataggACCCTCTCTGTCGCTCCCAAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6841 
LmxM.04.06
80 gaaattaatacgactcactataggAGAGTGGGGAAGGGTGGATAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6844 
LmxM.05.09
30 gaaattaatacgactcactataggGAGAACAGGGGTGGGGGTGGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6847 
LmxM.07.08
50 gaaattaatacgactcactataggTGCGTGTGTGTATGTGTGTAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6850 
LmxM.13.15
80 gaaattaatacgactcactataggGTGCAAGTGAATATGTTGTCgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6853 
LmxM.22.06
10 gaaattaatacgactcactataggCTCTTGCTTCCTTCACAAGCgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6856 
LmxM.24.17
10 gaaattaatacgactcactataggTGTACAGTGTGTCTTCAAATgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6859 
LmxM.24.21
30 gaaattaatacgactcactataggCAACGCGCTTCTCTGGTCTTgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6862 
LmxM.31.07
00 gaaattaatacgactcactataggGTGGTGGCGGCTGGGATCTGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6865 
LmxM.31.09
60 gaaattaatacgactcactataggTGATGATGATGATGCCACTTgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6868 
LmxM.32.27
70 gaaattaatacgactcactataggCTTGTAGCGAGGAGTAGGAAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6871 
LmxM.33.09
00 gaaattaatacgactcactataggACAGGTGGGAAGGCGAGTTAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
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OL6874 
LmxM.33.15
55 gaaattaatacgactcactataggCGACGGCTCGTGTCGTTTTTgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6877 
LmxM.34.13
00 gaaattaatacgactcactataggTGTTGTTTTTCTTTCCTTTCgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6880 
LmxM.24.21
40 gaaattaatacgactcactataggGTCGATGAGGATGATACACGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6883 
LmxM.23.05
50 gaaattaatacgactcactataggCGCGCCTGAGTGTGAGTGCGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6886 
LmxM.34.30
60 gaaattaatacgactcactataggTTGTGCTTTGCGCTGTGTTTgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6889 
LmxM.08.02
20 gaaattaatacgactcactataggCTACGCTACTCGTTACTTTGgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL6892 
LmxM.01.07
10 gaaattaatacgactcactataggACGACGGCGTAGATGCGCGAgttttagagctagaaatagc Forward 
5' sgRNA 
primer 
OL7153 
LmxM.36.63
40 
ACCCCCCCTCCCCTGAGCATCGCAGGTGATTAATACGACTCACTATAAAAC
TGGAAGAAATTAACCCTTgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7154 
LmxM.36.63
40 GAAGGGGAGGCGGCGCAAACGAAACGACCCccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7155 
LmxM.36.63
40 gaaattaatacgactcactataggTAGCAGGGCGTATCGAACGTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7156 
LmxM.29.09
10 
GGTCGACGTCGGCTTGCCTCGCAGCTCCCTTAATACGACTCACTATAAAAC
TGGAAGTTGCATGTGGCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7157 
LmxM.29.09
10 CTCGTTCGTACTGCTCCACGAAGCCCACCGccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
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null mutant 
generation 
OL7158 
LmxM.29.09
10 gaaattaatacgactcactataggCGTGGCGCTACAACGCGTCTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7159 
LmxM.07.02
80 
CCCCCTCTCTCTGTTTCTCGGCGAGACCCTTAATACGACTCACTATAAAACT
GGAAGCCCGGAACCCTTgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7160 
LmxM.07.02
80 CGCACACGCCTCTGCCCCCTCCCCCTCCCCccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7161 
LmxM.07.02
80 gaaattaatacgactcactataggAGTAGTAGAGTGGGGGGAGGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7162 
LmxM.13.14
70 
CCTCGTCCGGCAACACACACACATACAGACTAATACGACTCACTATAAAAC
TGGAAGAACGTTGTGTCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7163 
LmxM.13.14
70 GAGCAAACATGCACCCCCTCCCCATCCCCTccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7164 
LmxM.13.14
70 gaaattaatacgactcactataggATCAGCTGCCACGTATGTGGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7165 
LmxM.36.43
70 
AACGCTGATATAGAGCCCACCACTCTCTTCTAATACGACTCACTATAAAACT
GGAAGGGGCCAACCCTTgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7166 
LmxM.36.43
70 CCCCTCCAACAAGCAAGCATCCCACGCCCGccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
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primer for 
null mutant 
generation 
OL7167 
LmxM.36.43
70 gaaattaatacgactcactataggGCACGTGGAGCTCTTTGACGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7168 
LmxM.26.23
70 
CGTGACCAGCTCAGGCACCTAGGGCAGCGGTAATACGACTCACTATAAAA
CTGGAAGCACACCATGTCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7169 
LmxM.26.23
70 CACGTCAGGAGCAACGCTGCATGGGCTCCGccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7170 
LmxM.26.23
70 gaaattaatacgactcactataggTCACCGCCGTAGACGGAAAGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7171 
LmxM.31.10
90 
TGGAGCACACCTCAGCCACGGTACATTCCGTAATACGACTCACTATAAAAC
TGGAAGTTTGGTTCCCGGgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7172 
LmxM.31.10
90 ACTCCGCAACAAACGTCTATACGGTCACATccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7173 
LmxM.31.10
90 gaaattaatacgactcactataggATAGCTGCTTTGACAGCCTGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7174 
LmxM.31.39
30 
GATCGTCCCGCGTGTCGCGGTCGTTGGTGATAATACGACTCACTATAAAAC
TGGAAGGTGTGCATGTCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
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OL7175 
LmxM.31.39
30 CTTCGCAGATACGTACGCATAGAAAGACGCccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7176 
LmxM.31.39
30 gaaattaatacgactcactataggGTCGGTGCACATGCTCGAGAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7177 
LmxM.33.39
60 
GTGATTGCTCTCGTTGTGGGGCCGACTTATTAATACGACTCACTATAAAACT
GGAAGCCCAATTCCCGGgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7178 
LmxM.33.39
60 GTGAGCCCTTCGCAACGGCGGGGCGCGGCTccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7179 
LmxM.33.39
60 gaaattaatacgactcactataggAAACAACCAAGCATGCCGCGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7180 
LmxM.34.24
50 
CCTTCAACCCTCCTCCACCCTTCCCTCCCTTAATACGACTCACTATAAAACT
GGAAGTGTGTCATGTCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7181 
LmxM.34.24
50 GATGCAACAGGCATAAATACAAAAGAGAAAccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7182 
LmxM.34.24
50 gaaattaatacgactcactataggCGAAAAGAGCGCGAGATGAAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7183 
LmxM.34.53
90 
AGAAAGATAGTTATCATCACGCGGCGGTGCTAATACGACTCACTATAAAAC
TGGAAGAAACCTTCCCGGgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
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null mutant 
generation 
OL7184 
LmxM.34.53
90 CAGATGAGCAACAGCACCAAAAGAAAAGGCccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7185 
LmxM.34.53
90 gaaattaatacgactcactataggGACAACGAAAGGAATGACGCgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7186 
LmxM.29.21
70 
GACACTGACGCGGCCGCGAATATATCTATTTAATACGACTCACTATAAAACT
GGAAGATGACGTTGTCCgtataatgcagacctgctgc Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL7187 
LmxM.29.21
70 CCTCTCTCCCCGTTTCCTGTACTGCTGCCAccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL7188 
LmxM.29.21
70 gaaattaatacgactcactataggTTCCTACCAGTCAGTGCTGTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL7994 
LmxM.36.63
40 AGTTTGGGTGGTTTCCGTGT Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL7995 
LmxM.36.63
40 GTATTTGCCGCGTTCTCGAC Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL7996 
LmxM.36.63
40 GAGTTTCTCGCGTCACCTCA Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
8 
 
OL7997 
LmxM.29.09
10 CCTCCTTGCCCACCAAAGAT Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL7998 
LmxM.29.09
10 GAGCGCACATACATTGCCAG Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL7999 
LmxM.29.09
10 TCTTTCGCTTTCAGGCTGTCT Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8001 
LmxM.07.02
80 AGCTGCAGAAGGTCAAGTCC Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8002 
LmxM.07.02
80 CTTACCGTTCGGCTCCAACT Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8003 
LmxM.07.02
80 AGGGTGGGTACATCAGTGCT Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8004 
LmxM.13.14
70 CAACGCTGCAACAGCTTCTT Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8005 
LmxM.13.14
70 AGTCACGACTGATCTCCCGA Reverse 
Within gene 
reverse (for 
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diagnostic 
PCR) 
OL8006 
LmxM.13.14
70 GGGCGCGCACTCATTTTTAT Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8007 
LmxM.36.43
70 TCCTCGTTGGACTCAAGCAC Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8008 
LmxM.36.43
70 GATCGGCGAACGATCTGACT Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8009 
LmxM.36.43
70 GCCACTCTCGTGGTTACTCA Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8011 
LmxM.26.23
70 CGTAATGGCACTCAATGGCG Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8012 
LmxM.26.23
70 GATACATGGCTCCCTCGTCG Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8013 
LmxM.26.23
70 CGGTCTCTACGCGATTCGTT Forward 
Forward 
upstream of 
5' HR region 
(for 
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diagnostic 
PCR) 
OL8349 
LmxM.31.10
90 ACCTTCGAGACGTTCCCAAC 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8350 
LmxM.31.10
90 CGCTGGTTGCAGTAAGGAGA 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8351 
LmxM.31.10
90 AACTGCTTCCGTCTGACGTT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8353 
LmxM.31.39
30 TGACGACAACGGTGGAAGAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8354 
LmxM.31.39
30 CCAAGCGCTTCGTAATGCTC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8355 
LmxM.31.39
30 TCACGTTGGTGGCGTTTTTC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8356 
LmxM.33.39
60 CAAGGTGAGGACCTGCTGAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
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OL8357 
LmxM.33.39
60 AGAACAGACTGCCCGTAAGC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8358 
LmxM.33.39
60 GGGATCCGGAGAAACAACCA 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8360 
LmxM.34.24
50 GATCTAGAGCGGTGGTTCCG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8361 
LmxM.34.24
50 TACCGCATGAGGTGCGATAC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8362 
LmxM.34.24
50 TGGAGGGCGAGAGAAGAACT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8364 
LmxM.34.53
90 CACGGTTGTGAAGGGCAAAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8365 
LmxM.34.53
90 CAATGATTTCGCAGGAGGCG 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8366 
LmxM.34.53
90 TCGTTCATCCTTCGGTGCAA 
Forward 
Forward 
upstream of 
5' HR region 
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(for 
diagnostic 
PCR) 
OL8367 
LmxM.29.21
70 TCGCAGTGGAACGCTACTTT 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL8368 
LmxM.29.21
70 GACCTGTTGCACAGGAGACA 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL8369 
LmxM.29.21
70 GCGATCTTTACTGCCAACGC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL8640 
LmxM.32.27
70 
GCACAGACACACATACACACACACACAGACTAATACGACTCACTATAAAAC
TGGAAGGCAATGCGCTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL8641 
LmxM.32.27
70 TACATCATCTCAGCAGACAGACATAACCAAccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL8642 
LmxM.32.27
70 gaaattaatacgactcactataggAACCTGGAACCAAGTGCGTTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL8643 
LmxM.24.21
40 
ATCACGTCAACCCTAACCGCATCCCCACCGTAATACGACTCACTATAAAAC
TGGAAGATTTCCTAGCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
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OL8644 
LmxM.24.21
40 GACGCAACAACAAGAATACATCGACCTCCTccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL8645 
LmxM.24.21
40 gaaattaatacgactcactataggGCGCCGGCGATGATGACAAGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9327 
BSD 
(blasticidin 
resistance 
gene) CACAAGGTCCCCCAGTAAAA Reverse 
Blasticidin 
resistance 
cassette for 
diagnostic 
PCRs 2 
OL9371 
LmxM.23.05
50 
TGCTGGCACTGGCGCACGTCAAGGTAACCATAATACGACTCACTATAAAAC
TGGAAGGGCTTCCGGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9372 
LmxM.23.05
50 CAAATCACCATTAGTCATCCTCTGTGGCCGccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9373 
LmxM.23.05
50 gaaattaatacgactcactataggCCGCGTGGTGTGGCCATCTAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9374 
LmxM.34.30
60  
CAGACACGAAAACATAGCTTCAAACTACCGTAATACGACTCACTATAAAACT
GGAAGCCTCAGTACCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9375 
LmxM.34.30
60  CCGGGTGGGGTGGGCATGGCCGGGGGGCGTccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
14 
 
OL9376 
LmxM.34.30
60 gaaattaatacgactcactataggGCAGCCAGCAGCTCCGGATTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9377 
LmxM.08.02
20 
TGTGGTGCGCCAAGAACGCCCACACGCCCATAATACGACTCACTATAAAAC
TGGAAGTTAGGCCGGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9378 
LmxM.08.02
20 TGATTCATGGCAAGTCGTCACCGCGGTCCAccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9379 
LmxM.08.02
20  gaaattaatacgactcactataggGTGCTTGCGTCTGGAGCACGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9380 
LmxM.01.07
10 
GTTTGAGCAACAAGCACCGGAGCAGTGCCTTAATACGACTCACTATAAAAC
TGGAAGAAGACGTACCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9381 
LmxM.01.07
10 TGACCAGCGGTAGAACCTCCGTTCGCCCCGccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9382 
LmxM.01.07
10  gaaattaatacgactcactataggACGACGGCGTAGATGCGCGAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9383 
LmxM.02.03
90 
CGCTTACAGGACGCAGGGTGTGTGGGGAACTAATACGACTCACTATAAAA
CTGGAAGGCTATATCGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9384 
LmxM.02.03
90 TCCCCAAGCCCCACACGCACACAAAAGCCTccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
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null mutant 
generation 
OL9385 
LmxM.02.03
90 gaaattaatacgactcactataggACGCGAGAGAAAGGTTGCGAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9386 
LmxM.04.06
80  
CGTTGTACGCCTCCCTTCGCTCCCCGTCCTTAATACGACTCACTATAAAAC
TGGAAGATATCTCTCCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9387 
LmxM.04.06
80 TGCACACGCACGCACGCACATGTCAGGCATccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9388 
LmxM.04.06
80  gaaattaatacgactcactataggAGGCATACACACATGTCACAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9389 
LmxM.05.09
30  
TCCCCGTGTGTCTTTGGACTCCTTCTGCCCTAATACGACTCACTATAAAACT
GGAAGCGATAATCGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9390 
LmxM.05.09
30  TACGTCGCGGCGCTACCGCCACTCCCCCCCccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9391 
LmxM.05.09
30 gaaattaatacgactcactataggTGTGTGTGTGTGTGTGTGGAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9392 
LmxM.07.08
50  
AAGTCAGGGGACCGACTCTCCCCTGTGCCGTAATACGACTCACTATAAAAC
TGGAAGTATAGTCTCCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9393 
LmxM.07.08
50 GCAGTCGCCCACCCCCACCCCCCACTGCCAccaatttgagagacctgtgc Reverse 
Downstream 
reverse 
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primer for 
null mutant 
generation 
OL9394 
LmxM.07.08
50 gaaattaatacgactcactataggCTGGAGAGGAACCAAAACGAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9395 
LmxM.13.15
80 
ATCTCTCCTCCCTCGGTGGTCTTTTCCCCATAATACGACTCACTATAAAACT
GGAAGTAGCGATCGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9396 
LmxM.13.15
80  AAAGCACCGAGACAATCAACAGTGGCTCCAccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9397 
LmxM.13.15
80  gaaattaatacgactcactataggTTTCGCAGTATCACACCCGCgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9398 
LmxM.22.06
10  
CTTTTTTAATTGGTGTGAGCGCCGTCTTTCTAATACGACTCACTATAAAACT
GGAAGCGCGATCTCCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9399 
LmxM.22.06
10 AACCAGGGAACTAGCCACGCACATGCCGACccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9400 
LmxM.22.06
10  gaaattaatacgactcactataggACACCGCACCTGTAGCAGTGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9401 
LmxM.24.17
10  
TTTTTCTCCTCGCTCACTTCATTTCAGATCTAATACGACTCACTATAAAACTG
GAAGATCGCATCGTGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
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OL9402 
LmxM.24.17
10  ACGACACGGCGAGGGCCCGCCAAGTCGTGCccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9403 
LmxM.24.17
10  gaaattaatacgactcactataggGGTGGAGCGCGTGAAGGCGGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9404 
LmxM.24.21
30 
CGTGCCTGCTCTTGTGCGCTTGCGTCGGTGTAATACGACTCACTATAAAAC
TGGAAGGCGCTTCTCCAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9405 
LmxM.24.21
30  ATCTCTAGGACCCAACAAACCACCGACTCAccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9406 
LmxM.24.21
30 gaaattaatacgactcactataggGTCACACACGCAACACGTAGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9407 
LmxM.31.07
00  
TCTTCTCCGTTGCTGTTTCTTGCTCCACCATAATACGACTCACTATAAAACT
GGAAGTGAATTACGCGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9408 
LmxM.31.07
00 ACACCTTCACGAGGAATGCCTCAAGCGCACccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9409 
LmxM.31.07
00 gaaattaatacgactcactataggGAGTAAGCGGTGGGTATAAGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9410 
LmxM.31.09
60 
AACGGAAGAAGAATTAAAAGGCGCCCTCCTTAATACGACTCACTATAAAAC
TGGAAGCATTCAGTCTAAgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
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null mutant 
generation 
OL9411 
LmxM.31.09
60 TCGTACGTCGCGCTGTTTTGGCTGCTACCGccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9412 
LmxM.31.09
60 gaaattaatacgactcactataggTCGACGTCACGGCCAGACCTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9413 
LmxM.33.09
00 
ACCAAAGAGTTCCAGTCCAGACCTTCCCCATAATACGACTCACTATAAAACT
GGAAGGGAAGAGGACGGgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9414 
LmxM.33.09
00 CTTCGTAGTTTATCAGAGGGAGGTTCGCCGccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9415 
LmxM.33.09
00  gaaattaatacgactcactataggAGTGAACACAGATCCCTAGGgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9416 
LmxM.33.15
5 
TCCTTCATGTTTGCTGGGGTTTTTTTTTCATAATACGACTCACTATAAAACTG
GAAGACGGCGCATTCCgtataatgcagacctgctgc 
Forward 
Upstream 
forward 
primer for 
null mutant 
generation 
OL9417 
LmxM.33.15
55  TTGACACGAAGTGGTTGCACAAGCGAGTATccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9418 
LmxM.33.15
55 gaaattaatacgactcactataggGACCGGGTACTAGTTCCGTAgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9419 
LmxM.34.13
00  
CCTATCTGTTCTGTTGCTCTCATCTCACCCTAATACGACTCACTATAAAACT
GGAAGCCTTCAGGAGGGgtataatgcagacctgctgc Forward 
Upstream 
forward 
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primer for 
null mutant 
generation 
OL9420 
LmxM.34.13
00  TCTTCGGTTCTCTCCTTGGTTTCACTTCCCccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
null mutant 
generation 
OL9421 
LmxM.34.13
00 gaaattaatacgactcactataggAAAGTGAATCCGGGAGCGGTgttttagagctagaaatagc Reverse 
3' sgRNA 
primer 
OL9479 
LmxM.32.27
70 CCAAAGGGTTTCTTCCGCAC 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9480 
LmxM.32.27
70 TGTTTGCCATGGACGATGCT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9481 
LmxM.32.27
70 CATTTCGGCACACGCTTTCA 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9482 
LmxM.24.21
40 GCATGGATTCTGCGTTGACC 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9483 
LmxM.24.21
40 GGTACAAAGACGCGCTTCAC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9484 
LmxM.24.21
40 AATGTACAAGCGCACCCACT 
Forward 
Forward 
upstream of 
5' HR region 
20 
 
(for 
diagnostic 
PCR) 
OL9545 
LmxM.23.05
50 ATTCTGGAGCGGTGCAAAGA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9546 
LmxM.23.05
50 ACGAGAGACGTGGTTGTCAC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9547 
LmxM.23.05
50 GAGGTCGGCGAATGAAAGGT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9548 
LmxM.34.30
60 GACTTTATCGCTGCGGCAAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9549 
LmxM.34.30
60 CCGTTCCACAGCATACCCTT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9550 
LmxM.34.30
60 TTTCATCTCGTACCCGCCTG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9551 
LmxM.01.07
10  CACCGTCGTCGACATGGATT 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
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OL9552 
LmxM.01.07
10 TGGGCCATGTGAATGACTCG 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9553 
LmxM.01.07
10 CTGTCGACATCGCTCCTAGTC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9554 
LmxM.02.03
90 TCCGTCTCTCCCTCAAGTACAA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9555 
LmxM.02.03
90  TAGCCCTTCCAATGATGCCT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9556 
LmxM.02.03
90 ATCGTGAGAGGGAGACGGG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 1 
OL9557 
LmxM.04.06
80 ACAACGCGCATTATCAAGGAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9558 
LmxM.04.06
80 GGCTCGACATGAGAATCTGGA 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9559 
LmxM.04.06
80 TGCCTCTTACCCATCCAACAC 
Forward 
Forward 
upstream of 
5' HR region 
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(for 
diagnostic 
PCR) 
OL9560 
LmxM.05.09
30 ACGCGTCTTCCTCCATCAAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9561 
LmxM.05.09
30 GCCTCCTTTGTTTCGAGTGC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9562 
LmxM.05.09
30  GACTCCGATCATCCCGTGTG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9563 
LmxM.07.08
50 CCGACCCGGACATTCATCTG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL9564 
LmxM.07.08
50 AGACTCGCGTAACCCTCCAT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL9565 
LmxM.07.08
50 AATCGAGATCCGCTTACCGC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL9754 
LmxM.07.02
80 TCGGCACGCGCGCTTGCGCAGGAGTCGATGccaatttgagagacctgtgc 
Reverse 
Downstream 
reverse 
primer for 
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null mutant 
generation 2 
OL9755 
LmxM.07.02
80 
gaaattaatacgactcactataggGGGAAGGGTTCCAATAGTTGGGGgttttagagctagaaa
tagc Forward 
5' sgRNA 
primer 2 
OL9756 
LmxM.07.02
80 
gaaattaatacgactcactataggTGGACACGCTGAGCGAGACCGGGgttttagagctagaa
atagc Reverse 
3' sgRNA 
primer 2 
OL10120 
LmxM.02.03
90 ACGCGCACGAATTCTTTTCC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) (2) 
OL10121 
LmxM.08.02
20  TACCTGGGGCTCTCGATTCA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10122 
LmxM.08.02
20 TTGAGTTCCCGACATCTGCC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10123 
LmxM.08.02
20 GTACGCACCTCCCAACACTT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10124 
LmxM.13.15
80 GAAACTTTCGCCTGCTGGA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10125 
LmxM.13.15
80 TCAGTACGTAGACCCCTCCG 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
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OL10126 
LmxM.13.15
80 TAAGCGCAATTCCATCCCGT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10127 
LmxM.22.06
10  GATCAACCTCAGCAGGGTGT 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10128 
LmxM.22.06
10 GCGCCTCTAGGTTAAGCGAT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10129 
LmxM.22.06
10 CGTGAAGAGGCCGCAAAAAT 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10132 
LmxM.24.17
10 CTCCCTTCCTTCTGCCAGTG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10166 
LmxM.31.07
00 TCCAGCTGCCATCCGATTAC 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10167 
LmxM.31.07
00 GTCCGTCAAACCCTTCGAGT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
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OL10168 
LmxM.31.07
00 TCTGGCTGATACCGACACAC 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10169 
LmxM.31.09
60 TGGACGAGTGTGCATTTCCA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10170 
LmxM.31.09
60 CGCCACGATGCTTGATTAGC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10171 
LmxM.31.09
60 CGCAGACTTGGCATCGAGTA 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10172 
LmxM.33.09
00 AGCTCTTACCACCCCGAGAA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10173 
LmxM.33.09
00 CGGGCTACAGCACCAGTAAT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10174 
LmxM.33.09
00 GGAAGAGGTTGCGTCCTTG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
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OL10175 
LmxM.33.15
55 TCTTAAGGAGCTGGCCAACAG 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10176 
LmxM.33.15
55 CTTGAACTCTTCAGGCGTTGC 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10177 
LmxM.33.15
55 TAGTCGCAGTTCGCAGAGTG 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10283 
LmxM.24.21
30 CGGCTGCAAAAGGAACTCGTA 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10284 
LmxM.24.21
30 GTACAGCGATGGTGAACTGCT 
Reverse 
Within gene 
reverse (for 
diagnostic 
PCR) 
OL10285 
LmxM.24.21
30 GATTCCTGCGGCTGTTCCTA 
Forward 
Forward 
upstream of 
5' HR region 
(for 
diagnostic 
PCR) 
OL10329 
LmxM.24.17
10 CATGCAGAAGCTGGATGGAGT 
Forward 
Within gene 
forward (for 
diagnostic 
PCR) 
OL10330 
LmxM.24.17
10 GATGATGTAGTTGCCGCCCAT Reverse 
Within gene 
reverse (for 
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diagnostic 
PCR) 
OL10540 
Recoded 
LmxM.13.15
80 TCCAGGGACCAGCAATGGTCGAGGTTCCGCGC 
Forward 
Forward 
primer for 
integration 
into pETFPP 
vectors 
OL10541 
Recoded 
LmxM.13.15
80 TGAGGAGAAGGCGCGTCAGTAGGTACTACCCTCC 
Reverse 
Reverse 
primer for 
integration 
into pETFPP 
vectors 
OL10602 
pETFPP 
vectors TAATACGACTCACTATAGGG 
Forward 
T7 
sequencing 
primer 
OL10603 
pETFPP 
vectors TATGCTAGTTATTGCTCAGCGGT 
Reverse 
T7 term 
sequencing 
primer 
OL10633 
pGL2813 
(recoded 
UBA1a) CACGGTGACCTGTGTCGTAA 
Forward Sequencing 
primer 
OL10634 
pGL2813 
(recoded 
UBA1a) GTTCTTCGGCTGCCGTTTTT 
Forward Sequencing 
primer 
OL10635 
pGL2813 
(recoded 
UBA1a) ATGGGACCAGAAACGGAAGG 
Forward Sequencing 
primer 
RB1 
Recoded 
LmxM.23.05
50 TCCAGGGACCAGCAATGCTTTCTGAGGAAGAGCAAAAAC Forward  
Forward 
primer for 
integration 
into pETFPP 
vectors 
RB2 
Recoded 
LmxM.23.05
50 TGAGGAGAAGGCGCGTTAAAAGCGATAGCGGTAGCGGATG Reverse 
Reverse 
primer for 
integration 
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into pETFPP 
vectors 
RB3 
Recoded 
LmxM.04.06
80 TCCAGGGACCAGCAATGTTGACCACTCGTATCATTAAGG Forward  
Forward 
primer for 
integration 
into pETFPP 
vectors 
RB4 
Recoded 
LmxM.04.06
80 TGAGGAGAAGGCGCGTCATGGTTTGGCGTACTTACGAG Reverse 
Reverse 
primer for 
integration 
into pETFPP 
vectors 
 
Plasmid name Description Backbone Resistance  Source 
pGL2662 
Template vector for 
PCR amplification of 
blasticidin resistance 
cassette for gene 
knockout NA Ampicillin 
pTBlast_v1, Gluenz 
lab, University of 
Oxford 
pGL2663 
Template vector for 
PCR amplification of 
G418 resistance 
cassette for gene 
knockout NA Ampicillin 
pTNeo_v1, Gluenz 
lab, University of 
Oxford 
pGL2667 
Template vector for 
PCR amplification of 
puromycin 
resistance cassette 
for gene knockout NA Ampicillin 
pTPuro_v1, Gluenz 
lab, University of 
Oxford 
pETFPP_4 
HIS-Im9-
3cProtease-ORF pETYSBLIC3c Kanamycin 
York Technology 
Facility 
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pGL2813 
UBA1a in 
pETFPP_4 pETFPP_4 Kanamycin Self-generated 
pGL2817 UBC2 in pETFPP_4 pETFPP_4 Kanamycin Self-generated 
pGL2837 UEV1 in pETFPP_4 pETFPP_4 Kanamycin Self-generated 
 
S3 Table. ,QGLYLGXDOYLDELOLW\DVVD\RIǻXEFǻXEFǻXHYDQGǻKHFWGXULQJD[HQLFDPDVWLJRWHGLIIHUHQWLDWLRQ Raw fluorescence (590 nm) 
readings and relative viabilities compared to the Cas9 T7 cell line are included. 
Experiment 1 
0 h 48 h 120 h 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
8452 
3731
3 
3856
4 
5501
8 36498 
1627
9 
4883
2 
4655
7 
5116
9 46109 
1086
2 
5069
6 
2429
6 
1691
4 15591 
8594 
3718
1 
3795
7 
5535
9 36876 
1668
4 
4775
0 
4329
5 
5109
8 46276 
1130
8 
4523
7 
1926
6 
1664
2 15236 
8725 
3808
1 
3690
2 
5881
8 38100 
1712
0 
4767
3 
3736
5 
4962
3 41846 
1142
2 
4377
9 
1722
2 
1667
2 15481 
8620 
3673
7 
3735
8 
5531
9 36852 
1704
4 
4506
0 
3730
4 
4156
9 43443 
1137
2 
4148
0 
1750
0 
1640
1 14850 
8659 
3668
2 
3960
6 
5875
1 37500 
1678
5 
4682
6 
4364
7 
4489
5 45494 
1140
0 
4614
3 
1808
0 
1641
4 14917 
8371 
3627
0 
4048
9 
5850
1 37343 
1627
4 
5781
7 
3848
4 
5653
5 50919 
1092
5 
5632
1 
2335
6 
1660
8 15192 
               
Experiment 2 
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0 h 48 h 120 h 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
Nega
tive 
T7 
Cas9 
pare
ntal 
ǻubc
1 
ǻubc
2 ǻuev1 
9856 
3810
2 
3792
6 
5608
2 41017 
1756
5 
5938
7 
4722
2 
5082
2 47819 
1418
3 
4264
8 
2259
0 
1908
0 18250 
1001
6 
3845
3 
3877
0 
5694
6 41503 
1827
5 
5338
3 
4265
3 
4883
7 49687 
1494
5 
3893
0 
2042
9 
1949
3 17989 
9990 
3857
2 
3805
9 
5646
6 41668 
1864
5 
5610
0 
4530
6 
5072
8 56363 
1495
6 
3836
5 
2008
7 
2000
0 18326 
9980 
3804
5 
3734
9 
5846
2 40373 
1830
6 
5656
2 
4651
9 
4747
8 50766 
1493
8 
3871
3 
2069
1 
1989
8 18012 
9974 
3768
8 
3746
4 
5657
7 41282 
1842
9 
5026
6 
4352
6 
4994
1 48353 
1466
5 
3958
3 
2101
9 
2038
0 18160 
9714 
3768
7 
3783
7 
5583
3 40204 
1759
0 
5011
8 
4643
0 
4276
1 48598 
1349
8 
3664
0 
2314
3 
1985
7 18807 
 
Experiment 1 
0 h 48 h 120 h 
Negative 
T7 Cas9 
parental ǻhect2 Negative 
T7 Cas9 
parental ǻhect2 Negative 
T7 Cas9 
parental ǻhect2 
21143 54662 54366 17452 52061 36335 13387 48159 15157 
21585 55822 54093 18396 53755 40325 13972 45988 15441 
21692 55745 54605 18383 53359 42512 13946 43715 15538 
21441 55740 54675 18420 52141 41370 13849 42746 15542 
21401 55370 55008 18401 52583 38966 13797 43026 15526 
21238 56019 54677 17856 52287 34640 13235 46959 15239 
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Experiment 2 
0 h 48 h 120 h 
Negative 
T7 Cas9 
parental ǻhect2 Negative 
T7 Cas9 
parental ǻhect2 Negative 
T7 Cas9 
parental ǻhect2 
26946 45285 57003 26946 45107 29833 22632 30187 14212 
28348 45175 40858 28348 45503 32500 35053 40382 14506 
28254 47848 57771 28254 46726 34150 28293 40316 14696 
28114 42693 57020 28114 47753 34330 26289 39611 14533 
27386 46252 53986 27386 48782 30720 26922 40196 13968 
27880 46024 43447 27880 45568 25247 29833 39931 13100 
 
Experiment 1 Experiment 2 Average 
 
Time into differentiation (h) 
 
Time into differentiation (h)  Time into differentiation (h) 
Cell 
line 0 48 120 
Cell 
line 0 48 120 
Cell 
line 0 48 120 
Cas9 
T7 1 1 1 
Cas9 
T7 1 1 1 
Cas9 
T7 1 1 1 
ǻubc1 1.05185 0.75587 0.24232 ǻubc1 0.99324 0.75042 0.27607 ǻubc1 1.02254 0.75315 0.2592 
ǻubc2 1.71697 1.00481 0.14957 ǻubc2 1.66158 0.83757 0.21344 ǻubc2 1.68928 0.92119 0.1815 
ǻuev1 1.01211 0.89745 0.11082 ǻuev1 1.10354 0.88834 0.15139 ǻuev1 1.05783 0.8929 0.1311 
ǻhect2 0.97103 0.60421 0.05444 ǻhect2 1.34611 0.17646 0 ǻhect2 1.15857 0.39034 0.02722 
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S4 Table. Data collection and refinement statistics for UBC2-UEV1 crystal structure. 
Data collection 
 
Space group P21 
Cell dimensions 
 
a, b, c (Å) 32.52, 72.56, 120.10 
ĮȕȖ 90, 91.84, 90 
Resolution (Å) a 46.25-1.70  (1.73 -1.70) 
Total No. of reflections  a 260,600 (14,037) 
No. of unique reflections  a 61,439 (3,267) 
Completeness (%)  a 100 (100) 
Multiplicity  a 4.2 (4.3) 
,ı,a 7.3 (1.2) 
Rmerge b 0.096 (1.449) 
Rpim c 0.050 (0.747) 
CC1/2 0.9967 (0.529) 
Overall B factor from Wilson plot (Å2) 26.32 
  
Refinement 
 
Resolution (Å) 46.29-1.70 
Rworkd / Rfree e 0.222 / 0.260 
No reflections (free) 61,440 / 3,018 
Completeness (%) 100 (99.7) 
No. of non-H atoms  
 
  Protein 4,652 
  Water 266 
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  Ion 5 
  Total 4,923 
B-factors   
 
Protein Main Chain   (Å2) 29.4 
Protein Side Chain   (Å2) 33.8 
Water  (Å2) 32.4 
R.m.s. deviationsf 
 
  Bonds (Å) 0.0087 
  Angles (°) 1.597 
Ramachandran plot g 96.41 / 2.51 / 1.08 
  
a
 Values in parentheses correspond to the outer resolution shell 
 
b
 Rmerge  hkli|Ii - <I!_hkliI where Ii is the intensity of the ith measurement of a reflection with indexes hkl 
and <I> is the statistically weighted average reflection intensity. 
c
 Rpim  hkl[1/(n-1)]1/2i|Ii - <I!_hkliI 
 
d
 Rfactor   __)o| - |Fc___)o| where Fo and Fc are the observed and calculated structure factor amplitudes, 
respectively.  
e
 Rfree is the R-factor calculated with 5 % of the reflections chosen at random and omitted from refinement 
f
 Root-mean-square deviation of bond lengths and bond angles from ideal geometry. 
g
 Percentage of residues in preferred/allowed/outlier regions.  
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Supplementary figure 1. Alignments of L. mexicana and H. sapiens protein sequences. 
Sequences obtained from TriTryDB (L. mexicana) and NCBI or UniProt (H. sapiens) were 
2 
 
aligned using T-Coffee. Residues in the local vicinity of the putative active site cysteine of A 
ubiquitin E1-activating enzymes, B E2-conjugating enzymes and C E3 ligase HECT domains 
are shown. Red boxes indicate amino acid identity, red characters show similarity within the 
highlighted group and blue frames highlight similarity across groups. Black bar indicates the 
position of the conserved HPN motif in E2 genes and the black triangles highlight the 
conserved catalytic cysteine residues in all classes of protein. L. mexicana genes are indicated 
with the prefix Lm and H. sapiens genes with the prefix Hs. Where no prefix is given, 
sequences belong to L. mexicana. 
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Supplementary figure 2. Confirmation of the null mutant library. A Schematic of PCRs 
performed to identify null mutants from heterozygotes or mutants with additional gene copies. 
Primers were designed to amplify regions within the gene of interest (red primers) and 
EHWZHHQ WKH¶-UTR of the gene and the blasticidin resistance cassette of the edited DNA 
(black primers). B PCRs performed on genomic DNA from parental (P) and mutant (M) cells 
are shown for genes that were deleted successfully. Due to the large size of HECT3 (18.6 
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kbp), only the first 8 kbp of the gene was targeted for editing. The HECT3 gene PCR was 
designed to amplify within the targeted region. C PCRs performed on genomic DNA from 
parental (P) and mutant (M) cells are shown for genes that could not be deleted (no mutant 
clones were obtained for UBC13). D Relative viability oIǻubc1ǻubc2, ǻuev1 and ǻhect2 
compared to the parental Cas9 T7 line during promastigote to amastigote differentiation. Time 
elapsed since the initiation of differentiation is marked on the x-axis. Data are an average of 
two independent experiments, each with 6 biological replicates. 
 
Supplementary figure 3. Structural analysis of the UBC2-UEV1 heterodimer. A 
Superposition of chains A and B for UBC2-UEV1 (dark green and dark blue, PDB ID: 6ZM3), 
HsUBE2N-UBE2V2 (darker green and darker blue, PDB ID: 1J7D) and ScUbc13-Mms2 (light 
green and light blue, PDB ID: 1JAT). Locations of the N- and C-termini are shown. B Zoom-in 
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of the interface between UBC2 and UEV1 showing residues thought to contribute most 
significantly to complex formation according to analysis in the program PISA (96). Residues 
are labelled in black for UBC2 and blue for UEV1. Residues are coloured by atom (red, 
oxygen; blue, nitrogen). Hydrogen bonds are denoted by dashed lines. C Superposition of 
UBC2-UEV1 onto the structure of the UBE2N-UBE2V2-Ub complex (PDB ID: 2GMI) (50) 
showing UBC2 (green) and UEV1 (blue) as space fill models and the positions of acceptor 
and donor ubiquitins (orange ribbons) obtained from the UBE2N-UBE2V2-Ub structure. C85 
is represented by black (carbon) and yellow (sulfur) spheres. K63 of ubiquitin is highlighted as 
cylinders coloured by atom (blue, nitrogen). 
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Supplementary figure 4. UBA1b cannot transfer ubiquitin to UBC2 in vitro. A Alignment of L. 
mexicana and H. sapiens ubiquitin protein sequences. Red boxes indicate amino acid identity, 
red characters show similarity within the highlighted group and blue frames highlight similarity 
across groups. B UBA1b and ubiquitin were incubated with UBC2, UEV1 and ATP as indicated 
in ubiquitination assay buffer for 30 min at 30°C. Samples were treated  with either reducing or 
non-reducing sample buffer and visualised by SDS-PAGE with InstantBlue stain.  
